<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease - Chande, N - 2015 | Cochrane Library</title> <meta content="Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease - Chande, N - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000067.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease - Chande, N - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000067.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD000067.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease" name="citation_title"/> <meta content="Nilesh Chande" name="citation_author"/> <meta content="London Health Sciences Centre ‐ Victoria Hospital" name="citation_author_institution"/> <meta content="nilesh.chande@lhsc.on.ca" name="citation_author_email"/> <meta content="Petrease H Patton" name="citation_author"/> <meta content="University of Western Ontario" name="citation_author_institution"/> <meta content="David J Tsoulis" name="citation_author"/> <meta content="Robarts Research Institute" name="citation_author_institution"/> <meta content="Benson S Thomas" name="citation_author"/> <meta content="University of Western Ontario" name="citation_author_institution"/> <meta content="John K MacDonald" name="citation_author"/> <meta content="Robarts Clinical Trials" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD000067.pub3" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/10/30" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000067.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000067.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000067.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Azathioprine [adverse effects, *therapeutic use]; Crohn Disease [drug therapy, *prevention &amp; control]; Immunosuppressive Agents [*therapeutic use]; Maintenance Chemotherapy [*methods]; Mercaptopurine [adverse effects, *therapeutic use]; Prodrugs [*therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000067.pub3&amp;doi=10.1002/14651858.CD000067.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000067.pub3&amp;doi=10.1002/14651858.CD000067.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000067.pub3&amp;doi=10.1002/14651858.CD000067.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000067.pub3&amp;doi=10.1002/14651858.CD000067.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000067.pub3&amp;doi=10.1002/14651858.CD000067.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000067.pub3&amp;doi=10.1002/14651858.CD000067.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000067.pub3&amp;doi=10.1002/14651858.CD000067.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000067.pub3&amp;doi=10.1002/14651858.CD000067.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000067.pub3&amp;doi=10.1002/14651858.CD000067.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000067.pub3&amp;doi=10.1002/14651858.CD000067.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000067.pub3&amp;doi=10.1002/14651858.CD000067.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000067.pub3&amp;doi=10.1002/14651858.CD000067.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000067.pub3&amp;doi=10.1002/14651858.CD000067.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000067.pub3&amp;doi=10.1002/14651858.CD000067.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000067.pub3&amp;doi=10.1002/14651858.CD000067.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000067.pub3&amp;doi=10.1002/14651858.CD000067.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000067.pub3&amp;doi=10.1002/14651858.CD000067.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000067.pub3&amp;doi=10.1002/14651858.CD000067.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000067.pub3&amp;doi=10.1002/14651858.CD000067.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000067.pub3&amp;doi=10.1002/14651858.CD000067.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000067.pub3&amp;doi=10.1002/14651858.CD000067.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000067.pub3&amp;doi=10.1002/14651858.CD000067.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000067.pub3&amp;doi=10.1002/14651858.CD000067.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="PMzGcYGP";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD000067\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD000067\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000067\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000067\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD000067.pub3",title:"Azathioprine or 6\\u2010mercaptopurine for maintenance of remission in Crohn\u0027s disease",firstPublishedDate:"Oct 30, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gut Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PMzGcYGP&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000067.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000067.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD000067.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD000067.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000067.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD000067.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD000067.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD000067.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD000067.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD000067.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4921 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD000067.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000067.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000067.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000067.pub3/full#CD000067-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000067.pub3/full#CD000067-sec-0054"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000067.pub3/full#CD000067-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000067.pub3/full#CD000067-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000067.pub3/full#CD000067-sec-0017"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000067.pub3/full#CD000067-sec-0018"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000067.pub3/full#CD000067-sec-0038"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000067.pub3/full#CD000067-sec-0053"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000067.pub3/appendices#CD000067-sec-0059"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/table_n/CD000067StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/table_n/CD000067StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000067.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000067.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000067.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000067.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000067.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD000067.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000067.pub3/information#CD000067-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Nilesh Chande</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000067.pub3/information#CD000067-cr-0003">Petrease H Patton</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000067.pub3/information#CD000067-cr-0004">David J Tsoulis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000067.pub3/information#CD000067-cr-0005">Benson S Thomas</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000067.pub3/information#CD000067-cr-0006">John K MacDonald</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/information/en#CD000067-sec-0063">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 30 October 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD000067.pub3">https://doi.org/10.1002/14651858.CD000067.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD000067-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000067-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000067-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000067-abs-0008">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD000067-abs-0001" lang="en"> <section id="CD000067-sec-0001"> <h3 class="title" id="CD000067-sec-0001">Background</h3> <p>The therapeutic role of azathioprine (AZA) and 6‐mercaptopurine (6‐MP) remains controversial due to their relatively slow onset of action and potential for adverse events. An updated meta‐analysis was performed to evaluate the efficacy of these agents for the maintenance of remission in quiescent Crohn's disease. </p> </section> <section id="CD000067-sec-0002"> <h3 class="title" id="CD000067-sec-0002">Objectives</h3> <p>To assess the efficacy of AZA and 6‐MP for maintenance of remission in quiescent Crohn's disease. </p> </section> <section id="CD000067-sec-0003"> <h3 class="title" id="CD000067-sec-0003">Search methods</h3> <p>We searched MEDLINE, EMBASE, and the Cochrane Library from inception to June 30, 2015.</p> </section> <section id="CD000067-sec-0004"> <h3 class="title" id="CD000067-sec-0004">Selection criteria</h3> <p>Randomized controlled trials of oral azathioprine or 6‐mercaptopurine compared to placebo or active therapy involving adult patients (&gt; 18 years) with quiescent Crohn's disease were considered for inclusion. Patients with surgically‐induced remission were excluded. </p> </section> <section id="CD000067-sec-0005"> <h3 class="title" id="CD000067-sec-0005">Data collection and analysis</h3> <p>At least two authors independently extracted data and assessed study quality using the Cochrane risk of bias tool. For dichotomous outcomes, we calculated the risk ratio (RR) and corresponding 95% confidence interval (CI). The primary outcome was maintenance of remission. Secondary outcomes included steroid sparing, adverse events, withdrawals due to adverse events and serious adverse events. All data were analyzed on an intention‐to‐treat basis. The overall quality of the evidence supporting the primary outcome and selected secondary outcomes was assessed using the GRADE criteria. </p> </section> <section id="CD000067-sec-0006"> <h3 class="title" id="CD000067-sec-0006">Main results</h3> <p>Eleven studies (881 participants) were included. Comparisons included AZA versus placebo (7 studies, 532 participants), AZA or 6‐MP versus mesalazine or sulfasalazine (2 studies, 166 participants), AZA versus budesonide (1 study, 77 participants), AZA and infliximab versus infliximab (1 study, 36 patients), 6‐MP versus methotrexate (1 study, 31 patients), and early AZA versus conventional management (1 study, 147 participants). Two studies were rated as low risk of bias. Four studies were rated as high risk of bias for being non‐blinded or single‐blind. Five studies were rated as unclear risk of bias. A pooled analysis of six studies (489 participants) showed that AZA (1.0 to 2.5 mg/kg/day) was significantly superior to placebo for maintenance of remission over a 6 to 18 month period. Seventy‐three per cent of patients in the AZA group maintained remission compared to 62% of placebo patients (RR 1.19, 95% CI 1.05 to 1.34). The number needed to treat for an additional beneficial outcome was nine. A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was low due to sparse data (327 events) and unclear risk of bias. A pooled analysis of two studies (166 participants) showed no statistically significant difference in the proportion of patients who maintained remission between AZA (1.0 to 2.5 mg/kg/day) or 6‐MP (1.0 mg/day) and mesalazine (3 g/day) or sulphasalazine (0.5 g/15 kg/day) therapy. Sixty‐nine per cent of patients in the AZA/6‐MP group maintained remission compared to 67% of mesalazine/sulphasalazine patients (RR 1.09, 95% CI 0.88 to 1.34). A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was low due to sparse data (113 events) and high or unclear risk of bias. One small study found AZA (2.0 to 2.5 mg/kg/day) to be superior to budesonide (6 to 9 mg/day) for maintenance of remission at one year. Seventy‐six per cent (29/38) of AZA patients maintained remission compared to 46% (18/39) of budesonide patients (RR 1.65, 95% CI 1.13 to 2.42). GRADE indicated that the overall quality of the evidence supporting this outcome was low due to sparse data (47 events) and high risk of bias. One small study found no difference in maintenance of remission rates at one year between combination therapy with AZA (2.5 mg/kg) and infliximab (5 mg/kg every 8 weeks) compared to infliximab monotherapy. Eighty‐one per cent (13/16) of patients in the combination therapy group maintained remission compared to 80% (16/20) of patients in the infliximab group (RR 1.02, 95% CI 0.74 to 1.40). GRADE indicated that the overall quality of the evidence supporting this outcome was very low due to very sparse data (29 events) and high risk of bias. One small study found no difference in maintenance of remission rates at one year between 6‐MP (1 mg/kg/day) and methotrexate (10 mg/week). Fifty per cent (8/16) of 6‐MP patients maintained remission at one year compared to 53% (8/15) of methotrexate patients (RR 0.94, 95% CI 0.47 to 1.85). GRADE indicated that the overall quality of the evidence supporting this outcome was very low due to very sparse data (16 events) and high risk of bias. One study (147 participants) failed to show any significant benefit for early azathioprine treatment over a conventional management strategy. In the early azathioprine treatment group 67% (11‐85%) of trimesters were spent in remission compared to 56% (29‐73%) in the conventional management group. AZA when compared to placebo had a significantly increased risk of adverse events (RR 1.29, 95% CI 1.02 to 1.64), withdrawal due to adverse events (3.12, 95% CI 1.59 to 6.09) and serious adverse events (RR 2.45, 95% CI 1.22 to 4.90). AZA/6‐MP also demonstrated a significantly higher risk of serious adverse events when compared to mesalazine or sulphasalazine (RR 9.37, 95% CI 1.84 to 47.7). Common adverse events included pancreatitis, leukopenia, nausea, allergic reaction and infection. </p> </section> <section id="CD000067-sec-0007"> <h3 class="title" id="CD000067-sec-0007">Authors' conclusions</h3> <p>Low quality evidence suggests that AZA is more effective than placebo for maintenance of remission in Crohn's disease. Although AZA may be effective for maintenance of remission its use is limited by adverse effects. Low quality evidence suggests that AZA may be superior to budesonide for maintenance of remission but because of small study size and high risk of bias, this result should be interpreted with caution. No conclusions can be drawn from the other active comparator studies because of low and very low quality evidence. Adequately powered trials are needed to determine the comparative efficacy and safety of AZA and 6‐MP compared to other active maintenance therapies. Further research is needed to assess the efficacy and safety of the use of AZA with infliximab and other biologics and to determine the optimal management strategy for patients with quiescent Crohn's disease. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD000067-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000067-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD000067-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD000067-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000067-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD000067-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD000067-abs-0005">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD000067-abs-0003" lang="en"> <h3>Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease</h3> <p><b>What is Crohn's disease?</b> <br/> Crohn's disease is a long‐term chronic inflammatory bowel disease that can affect any part of the gastrointestinal tract from mouth to anus. Symptoms include abdominal pain, diarrhea and weight loss. When people with Crohn's disease are experiencing symptoms of the disease it is said to be ‘active’. Periods when the symptoms stop are called ‘remission’. </p> <p><b>What are azathioprine and 6‐mercaptopurine?</b> <br/> Azathioprine and 6‐mercaptopurine are oral medications that reduce the body's immune responses and may reduce inflammation associated with Crohn's disease. </p> <p><b>What did the researchers investigate?</b> <br/> The researchers investigated whether azathioprine or 6‐mercaptopurine maintains remission in people with inactive Crohn's disease and whether these medications cause any harms (side effects). The researchers searched the medical literature up to June 30, 2015. </p> <p><b>What did the researchers find?</b> <br/> The researchers identified 11 studies that included a total of 881 participants. Seven studies including 532 participants compared azathioprine to a placebo (a fake medicine such as a sugar pill). Two studies including 166 participants compared azathioprine or 6‐mercaptopurine to aminosalicylates (the anti‐inflammatory medications mesalazine or sulfasalazine). One study including 77 participants compared azathioprine to budesonide (a steroid drug). One study including 31 participants compared 6‐mercaptopurine to methotrexate (an immunosuppressive drug). One study including 36 participants compared combination therapy with azathioprine and infliximab (a biologic drug) to infliximab alone. One study with 147 participants compared the early use of azathioprine in patients with recently diagnosed Crohn's disease to a conventional management strategy. Two studies were rated as high quality. Three studies were rated as low quality. Six studies were rated as unclear quality due to a lack of information. </p> <p>A pooled analysis of six studies (489 participants) suggests that azathioprine (at daily doses of 1.0 to 2.5 mg/kg/day) is superior to placebo for maintenance of remission of Crohn's disease over a 6 to 18 month period. A pooled analysis of two studies (166 participants) showed no difference in the proportion of patients who maintained remission between azathioprine (1.0 to 2.5 mg/kg/day) or 6‐mercaptopurine (1.0 mg/day) and aminosalicylate therapy (mesalazine 3 g/day or sulfasalazine 0.5g/15 kg/day). One small study (77 participants) suggests that azathioprine (2.0 to 2.5 mg/kg/day) may be superior to budesonide (6 to 9 mg/day) for maintenance of remission over a one year period. One small study (36 participants) found no difference in maintenance of remission rates at one year between combination therapy with azathioprine (2.5 mg/kg/day) and infliximab (5 mg/kg every 8 weeks) compared to infliximab alone. One small study (31 participants) found no difference in maintenance of remission rates at one year between 6‐mercaptopurine (1 mg/day) and methotrexate (10 mg/week). One study (147 participants) failed to show any difference in time spent in remission between early azathioprine treatment and a conventional management strategy. An increased risk of side effects was seen in participants who received azathioprine. Some of these side effects such as leukopenia (a reduction in the number of white cells in the blood) were serious in nature. Common side effects included pancreatitis (inflammation of the pancreas), leukopenia, nausea, allergic reaction and infection. The choice to use azathioprine or 6‐mercaptopurine should be made after careful consideration of the risks and benefits of using these drugs. More research is needed to allow conclusions about the comparative effectiveness and side effects of azathioprine and 6‐mercaptopurine compared to other maintenance therapies such as methotrexate. Further research is needed to assess the effectiveness and side effects of the use of azathioprine with infliximab and other biologics and to determine the optimal management strategy for patients with inactive Crohn's disease. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD000067-sec-0054" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000067-sec-0054">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000067-sec-0091">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD000067-sec-0054"></div> <h3 class="title" id="CD000067-sec-0055">Implications for practice</h3> <section id="CD000067-sec-0055"> <p>Low quality evidence suggests that azathioprine is more effective than placebo for maintenance of remission in Crohn's disease. Although azathioprine may be effective for maintenance of remission its use may be limited by the potential for adverse events. Low quality evidence suggests that azathioprine may be superior to budesonide for maintenance of remission but because of small study size and high risk of bias, this result should be interpreted with caution. No conclusions can be drawn from the other active comparator studies because of low and very low quality evidence. The choice to use antimetabolite therapy should be individualized, and therapy should be undertaken only after a careful discussion of the risks and benefits with the patient. </p> </section> <h3 class="title" id="CD000067-sec-0056">Implications for research</h3> <section id="CD000067-sec-0056"> <p>Adequately powered trials are needed to determine the comparative efficacy and safety of azathioprine and 6‐mercaptopurine compared to other active maintenance therapies. Further research is needed to assess the efficacy and safety of the use of azathioprine with infliximab and other biologics and to determine the optimal management strategy for patients quiescent Crohn's disease. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD000067-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD000067-sec-0015"></div> <div class="table" id="CD000067-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine versus placebo for maintenance of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Azathioprine or 6‐mercaptopurine versus placebo for maintenance of remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> maintenance of remission in Crohn's disease<br/> <b>Setting:</b> Outpatient<br/> <b>Intervention:</b> Azathioprine or 6‐mercaptopurine<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with azathioprine or 6‐mercaptopurine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maintenance of remission (sensitivity analysis excluding Candy 1995)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>617 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>734 per 1000<br/> (648 to 827) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.19<br/> (1.05 to 1.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>489<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>249 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>321 per 1000<br/> (254 to 408) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.29<br/> (1.02 to 1.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>359<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>78 per 1000<br/> (40 to 152) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.12<br/> (1.59 to 6.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>661<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>3,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>71 per 1000<br/> (35 to 142) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.45<br/> (1.22 to 4.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>556<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> VERY LOW<sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Placebo group risk estimate come from the placebo arm of meta‐analysis, based on included trials<br/> <sup>2</sup> Downgraded one level due to sparse data (327 events).<br/> <sup>3</sup> Downgraded one level due to unclear risk of bias. Five of the studies in the pooled analysis were rated as unclear risk of bias for random sequence generation, allocation concealment or incomplete outcome data.<br/> <sup>4</sup> Downgraded one level due to sparse data (104 events).<br/> <sup>5</sup> Downgraded two levels due to very sparse data (37 events).<br/> <sup>6</sup> Downgraded one level due to unclear risk of bias. Two of the studies in the pooled analysis were rated as unclear risk of bias for random sequence generation, allocation concealment, blinding or incomplete outcome data.<br/> <sup>7</sup> Downgraded two levels due to very sparse data (31 events). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000067-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine versus mesalazine or sulfasalazine for maintenance of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Azathioprine or 6‐mercaptopurine versus mesalazine or sulfasalazin</b> e<b>for maintenance of remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> maintenance of remission in Crohn's disease<br/> <b>Setting:</b> Outpatient<br/> <b>Intervention:</b> Azathioprine or 6‐mercaptopurine<br/> <b>Comparison:</b> Mesalazine or sulfasalazine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with mesalazine or sulfasalazine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with azathioprine or 6‐mercaptopurine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maintenance of remission</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>667 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>727 per 1000<br/> (587 to 894) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.09<br/> (0.88 to 1.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 8.77<br/> (0.54 to 142.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45<br/> (1 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>126 per 1000<br/> (59 to 270) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.86<br/> (0.87 to 3.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>290<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 9.37<br/> (1.84 to 47.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>235<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk estimate come from the control arm of meta‐analysis, based on included trials<br/> <sup>2</sup> Downgraded one level due to unclear and high risk of bias. One study was rated as unclear risk of bias for random sequence generation and incomplete outcome data and the other study was rated as high risk of bias for no blinding.<br/> <sup>3</sup> Downgraded one level due to sparse data (113 events).<br/> <sup>4</sup> Downgraded one level due to high risk of bias.<br/> <sup>5</sup> Downgraded two levels due to very sparse data (8 events).<br/> <sup>6</sup> Downgraded two levels due to very sparse data (28 events).<br/> <sup>7</sup> Downgraded two levels due to very sparse data (16 events). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000067-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Azathioprine versus budesonide for maintenance of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Azathioprine versus budesonide for maintenance of remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> maintenance of remission in Crohn's disease </p> <p><b>Setting:</b> Outpatient<br/> <b>Intervention:</b> Azathioprine<br/> <b>Comparison:</b> Budesonide </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with budesonide</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with azathioprine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maintenance of remission</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>462 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>762 per 1000<br/> (522 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.65<br/> (1.13 to 2.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.13<br/> (0.25 to 103.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.13<br/> (0.25 to 103.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk estimate come from the control arm of meta‐analysis, based on included trials<br/> <sup>2</sup> Downgraded one level due to high risk of bias (no blinding).<br/> <sup>3</sup> Downgraded one level due to sparse data (47 events).<br/> <sup>4</sup> Downgraded two levels due to very sparse data (2 events). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000067-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Azathioprine and infliximab versus infliximab for maintenance of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Azathioprine and infliximab versus infliximab for maintenance of remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> maintenance of remission in Crohn's disease<br/> <b>Setting:</b> Outpatient<br/> <b>Intervention:</b> Azathioprine<br/> <b>Comparison:</b> Infliximab </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with infliximab</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with azathioprine +</b> </p> <p><b>infliximab</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maintenance of remission</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>800 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>816 per 1000<br/> (592 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.02<br/> (0.74 to 1.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>160 per 1000<br/> (33 to 786) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.60<br/> (0.33 to 7.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.42<br/> (0.10 to 56.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.42<br/> (0.10 to 56.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk estimate come from the control arm of meta‐analysis, based on included trials.<br/> <sup>2</sup> Downgraded one level due to high risk of bias (single‐blind).<br/> <sup>3</sup> Downgraded two levels due to very sparse data (29 events).<br/> <sup>4</sup> Downgraded two levels due to very sparse data (6 events).<br/> <sup>5</sup> Downgraded two levels due to very sparse data (1 event). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000067-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">6‐Mercaptopurine versus methotrexate for maintenance of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>6‐Mercaptopurine versus methotrexate for maintenance of remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> maintenance of remission in Crohn's disease<br/> <b>Setting:</b> Outpatient<br/> <b>Intervention:</b> 6‐mercaptopurine<br/> <b>Comparison:</b> Methotrexate </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with methotrexate</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with 6‐mercaptopurine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maintenance of remission</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>533 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>501 per 1000<br/> (251 to 987) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.94<br/> (0.47 to 1.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>407 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>265 per 1000<br/> (126 to 562) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.65<br/> (0.31 to 1.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>148 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>101 per 1000<br/> (25 to 407) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.68<br/> (0.17 to 2.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>148 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>101 per 1000<br/> (25 to 407) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.68<br/> (0.17 to 2.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk estimate come from the control arm of meta‐analysis, based on included trials.<br/> <sup>2</sup> Downgraded one level due to high risk of bias (no blinding).<br/> <sup>3</sup> Downgraded two levels due to very sparse data (16 events).<br/> <sup>4</sup> Downgraded two levels due to very sparse data (19 events).<br/> <sup>5</sup> Downgraded two levels due to very sparse data (7 events). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD000067-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000067-sec-0016">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000067-sec-0068">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD000067-sec-0016"></div> <p>The antimetabolite 6‐mercaptopurine and its prodrug, azathioprine, are purine analogues that inhibit cell growth by directly interfering with nucleic acid synthesis. Because of their ability to impede the rapid cell proliferation involved in inflammatory processes, these drugs have been shown to demonstrate immuno‐suppressive abilities (<a href="./references#CD000067-bbs2-0055" title="SahasranamanS , HowardD , RoyS . Clinical pharmacology and pharmacogenetics of thiopurines. European Journal of Clinical Pharmacology2008;64:753‐67. ">Sahasranaman 2008</a>). </p> <p>There have been many uncontrolled studies evaluating the efficacy of azathioprine for the therapy of Crohn's disease, and the first randomized, double‐blind, placebo‐controlled trials were documented in the early 1970's (<a href="./references#CD000067-bbs2-0054" title="RhodesJ , BaintonD , BeckP . Azathioprine in Crohn's disease. Lancet1970;2:1142. ">Rhodes 1970</a>; <a href="./references#CD000067-bbs2-0011" title="WilloughbyJM , BeckettJ , KumarPJ , DawsonAM . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2:944‐7. WilloughbyJM , KumarP , BeckettJ , DawsonAM . A double‐blind trial of azathioprine in Crohn's disease. Gut1971;12(10):864. ">Willoughby 1971</a>). Although much experience has been gained with these drugs since then, the therapeutic role of azathioprine and 6‐mercaptopurine remains controversial, in part related to their slow acting therapeutic effect as well as their potential for adverse events, such as leukopenia, pancreatitis, nausea, hypersensitivity, and increased risk of malignancy (<a href="./references#CD000067-bbs2-0044" title="GearryRB , BarclayML , BurtMJ , CollettJA , ChapmanBA . Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiology and Drug Safety2004;13(8):563‐7. ">Gearry 2004</a>). </p> <p>Crohn's disease is characterized by its propensity to relapse. Therefore studies were designed to determine the efficacy of azathioprine or 6‐mercaptopurine for maintenance of remission. This systematic review is an update of a previously published Cochrane review (<a href="./references#CD000067-bbs2-0059" title="PrefontaineE , SutherlandLR , MacDonaldJK , CepoiuM . Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD000067.pub2] ">Prefontaine 2009</a>). </p> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD000067-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000067-sec-0017">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000067-sec-0069">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD000067-sec-0017"></div> <p>The primary objective was to assess the efficacy and safety of azathioprine or 6‐mercaptopurine maintenance therapy in patients with quiescent Crohn's disease. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD000067-sec-0018" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000067-sec-0018">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000067-sec-0070">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD000067-sec-0018"></div> <section id="CD000067-sec-0019"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD000067-sec-0020"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials were considered for inclusion.</p> </section> <section id="CD000067-sec-0021"> <h4 class="title">Types of participants</h4> <p>Patients greater than 18 years of age with quiescent Crohn's disease (as defined by the included studies) were considered for inclusion. Quiescent disease, or disease in remission was defined as mild or absent symptoms prior to entering the study or by a validated index (e.g. CDAI &lt; 150), irrespective of the use of prophylactic medication. Patients with surgically‐induced remission were excluded. </p> </section> <section id="CD000067-sec-0022"> <h4 class="title">Types of interventions</h4> <p>Studies comparing oral azathioprine or 6‐mercaptopurine to placebo or an active therapy for maintenance of remission in Crohn's disease were included. </p> </section> <section id="CD000067-sec-0023"> <h4 class="title">Types of outcome measures</h4> <p>Most of the included studies used the Crohn's Disease Activity Index (CDAI) to define remission (<a href="./references#CD000067-bbs2-0040" title="BestWR , BecktelJM , SingletonJW , KernFJr . Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology1976;70:439–44. ">Best 1976</a>). Using the CDAI, remission is defined as a score of less than 150. The earlier studies utilized other scales such as the Disease Activity Score (DAS) (<a href="./references#CD000067-bbs2-0043" title="DyerN . Studies on Crohn's disease. MD Thesis University of Cambridge1970. ">Dyer 1970</a>), and other less well defined measures such as maintenance of well being. Despite this diversity in outcome measurement, we felt that these earlier studies provided a reasonable measurement of clinically active and inactive disease. </p> <section id="CD000067-sec-0024"> <h5 class="title">Primary outcomes</h5> <p>The primary outcome was maintenance of remission (as defined by the included studies, e.g. CDAI &lt; 150) at study endpoint. </p> </section> <section id="CD000067-sec-0025"> <h5 class="title">Secondary outcomes</h5> <p>Secondary outcomes included:</p> <p> <ol id="CD000067-list-0001"> <li> <p>adverse events</p> </li> <li> <p>withdrawal due to adverse events;</p> </li> <li> <p>serious adverse events; and</p> </li> <li> <p>steroid sparing.</p> </li> </ol> </p> </section> </section> </section> <section id="CD000067-sec-0026"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD000067-sec-0027"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases from inception to June 30, 2015:</p> <p> <ol id="CD000067-list-0002"> <li> <p>MEDLINE (Ovid);</p> </li> <li> <p>EMBASE (Ovid);</p> </li> <li> <p>Cochrane Library.</p> </li> </ol> </p> <p>Conference proceedings were also searched to identify additional studies.</p> <p>The electronic search strategies are reported in <a href="./appendices#CD000067-sec-0060">Appendix 1</a>. </p> </section> </section> <section id="CD000067-sec-0028"> <h3 class="title" id="CD000067-sec-0028">Data collection and analysis</h3> <section id="CD000067-sec-0029"> <h4 class="title">Selection of studies</h4> <p>Study titles and abstracts identified by the literature search were reviewed and potentially relevant studies were identified for full text evaluation. The studies selected for full text review were independently assessed by two authors (PHP and JKM or DJT or BST) and consensus for study inclusion and exclusion was reached through discussion. </p> </section> <section id="CD000067-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>Each study was reviewed and remission and safety data were independently extracted by at least two authors (PHP and JKM or DJT or BST). If data were missing or unclear, the study authors were contacted for clarification. </p> <p>Other information extracted from the studies included:</p> <p>a. Study characteristics and design;<br/> b. Characteristics of patients;<br/> c. Inclusion and exclusion criteria;<br/> d. Interventions; and<br/> e. Outcomes scoring methods. </p> </section> <section id="CD000067-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>At least two authors (PHP or JKM or DST or BST) independently assessed study quality using the Cochrane risk of bias tool (<a href="./references#CD000067-bbs2-0049" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). Items assessed included: </p> <p> <ol id="CD000067-list-0003"> <li> <p>Random sequence generation;</p> </li> <li> <p>Allocation concealment;</p> </li> <li> <p>Blinding of participants, personnel and assessment of outcome;</p> </li> <li> <p>Incomplete outcome data;</p> </li> <li> <p>Selective reporting;</p> </li> <li> <p>Other biases.</p> </li> </ol> </p> <p>Each category was evaluated as low, high or unclear risk and judgment justification was provided in the <a href="./references#CD000067-sec-0066" title="">Characteristics of included studies</a> section of the review. </p> <p><b>GRADE Analysis</b> </p> <p>The overall quality of the evidence supporting the primary outcome and selected secondary outcomes was evaluated using the GRADE approach (<a href="./references#CD000067-bbs2-0047" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. ">Guyatt 2008</a>; <a href="./references#CD000067-bbs2-0056" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011</a>). Using this approach outcome data were rated high, moderate, low or very low quality. Outcome data from randomized controlled trials begins as high quality but can be downgraded based on a number of criteria. These criteria include: </p> <p> <ol id="CD000067-list-0004"> <li> <p>Risk of bias in the included studies;</p> </li> <li> <p>Indirect evidence (by comparison, population, setting);</p> </li> <li> <p>Inconsistency (i.e. unexplained heterogeneity);</p> </li> <li> <p>Imprecise results (i.e. wide confidence intervals); and</p> </li> <li> <p>Likelihood of publication bias.</p> </li> </ol> </p> </section> <section id="CD000067-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, we calculated the risk ratio (RR) and corresponding 95% confidence interval. </p> </section> <section id="CD000067-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>For multi‐arm trials with a single placebo group and two treatment dose groups we split the placebo group in half to avoid a unit of analysis error (<a href="./references#CD000067-bbs2-0050" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). To avoid potential carry‐over effects we only included the first part of the study (i.e. before the cross‐over) for any cross‐over studies (<a href="./references#CD000067-bbs2-0050" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). </p> </section> <section id="CD000067-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>Data were analysed on an intention‐to‐treat basis. Studies were evaluated for missing data and where explanations were not provided, the patient outcome was considered to be a failure and counted as a relapse. </p> </section> <section id="CD000067-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>Statistical heterogeneity was assessed using the Chi<sup>2</sup> test and I<sup>2</sup> statistic. For the Chi<sup>2</sup> test a P value of less than 0.1 was considered to be statistically significant. The degree of statistical heterogeneity was quantified using the I<sup>2</sup> statistic. We investigated heterogeneity by visually inspecting the forest plots to identify outliers. If outliers were identified, we conducted sensitivity analysis to explore potential explanations for the heterogeneity. </p> </section> <section id="CD000067-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>If protocols were not available for the included studies, we assessed reporting bias by comparing the outcomes specified in the methods section of the manuscript to those reported in the results section. If there was more than 10 included studies in a pooled analysis, we planned to investigate publication bias by constructing funnel plots. </p> </section> <section id="CD000067-sec-0037"> <h4 class="title">Data synthesis</h4> <p>Data from individual trials were combined for meta‐analysis when the interventions, patient groups and outcomes were sufficiently similar (determined by consensus). We calculated the pooled RR and 95% CI for dichotomous outcomes using a fixed‐effect model. If significant heterogeneity was identified a random‐effects model was used. We performed subgroup analyses by dose of azathioprine or 6‐mercaptopurine (i.e. 1.0, 2.0, and 2.5 mg/kg/day). It was deemed acceptable to pool studies of azathioprine with 6‐mercaptopurine studies, as azathioprine is metabolized to 6‐mercaptopurine. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD000067-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD000067-sec-0038"></div> <section id="CD000067-sec-0039"> <h3 class="title">Description of studies</h3> <section id="CD000067-sec-0040"> <h4 class="title">Results of the search</h4> <p>A literature search conducted on June 30, 2015 identified 1541 studies. After duplicates were removed a total of 1119 studies remained for review of titles and abstracts. Fifty‐seven studies of azathioprine or 6‐mercaptopurine therapy for maintenance of remission in Crohn's were selected for full text review (See <a href="#CD000067-fig-0001">Figure 1</a>). Thirty‐five reports of 27 studies were excluded because they did not meet the inclusion criteria. The remaining 22 reports of 11 studies were evaluated for qualitative analysis and 11 studies underwent quantitative analysis. </p> <div class="figure" id="CD000067-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD000067-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD000067-sec-0041"> <h4 class="title">Included studies</h4> <p>Eleven trials (881 participants) were included (<a href="./references#CD000067-bbs2-0001" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. CandyS , WrightJP , GerberM , AdamsG , GerigM , GoodmanR . A double blind controlled study of azathioprine in the treatment and maintenance of remission in Crohn's disease [abstract]. Gastroenterology1994;106:A659. ">Candy 1995</a>; <a href="./references#CD000067-bbs2-0002" title="CosnesJ , BourrierA , BouhnikY , LaharieD , NahonS , BonnetJ , et al. Accelerated step‐care therapy with early azathioprine (AZA) vs. conventional step‐care therapy in Crohn's disease: a randomized study. Gastroenterology2012;142(5 Suppl 1):S161. CosnesJ , BourrierA , LaharieD , NahonS , BouhnikY , CarbonnelF , et al. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology2013;145(4):758‐65.e2; quiz e14‐5. ">Cosnes 2013</a>; <a href="./references#CD000067-bbs2-0003" title="ColombelJF , LemannM , BouhnikY , DuclosB , SouleJC , LereboursE , et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology2003;124(4 Suppl 1):A196‐7. LemannM , BouhnikY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. Randomized, double‐blind, placebo‐controlled, multicenter, azathioprine (AZA) withdrawal trial in Crohn’s disease (CD). Gastroenterology2002;122(4 Suppl 1):A23. LémannM , MaryJY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. A randomized, double‐blind, controlled withdrawal trial in Crohn's disease patients in long‐term remission on azathioprine. Gastroenterology2005;128(7):1812‐8. ">Lémann 2005</a>; <a href="./references#CD000067-bbs2-0004" title="MantzarisGJ , PloyzouP , KaragiannidisA , ChristidouA , KoilakouS , TsounisD , et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid‐dependent Crohn's disease. Gastroenterology2004;126:A54. ">Mantzaris 2004</a>; <a href="./references#CD000067-bbs2-0005" title="MantzarisG , ChristidouA , SfakianakisM , RoussosA , KoilakouS , PetrakiK , et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn's disease. Inflammtory Bowel Diseases2009;15:375‐82. MantzarisGJ , PetrakiK , Chadio‐IordanidesH , ChristidouA , KaragiannidisA , GlarakisJ , et al. Maintenance therapy with azathioprine is superior to budesonide in healing endoscopic lesions and improving histology in clinically quiescent Crohn's disease. Gastroenterology2002;122(4 Suppl 1):A81. ">Mantzaris 2009</a>; <a href="./references#CD000067-bbs2-0006" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero PernoaJ , Moreno OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12:1227‐33. ">Maté‐Jiménez 2000</a>; <a href="./references#CD000067-bbs2-0007" title="O'DonoghueDP , DawsonAM , Powell‐TuckJ . Azathioprine as a maintenance treatment for Crohn's disease: a double blind withdrawal trial. Gastroenterology1978;72(5 II):1138. O'DonoghueDP , DawsonAM , Powell‐TuckJ , BownRL , Lennard‐JonesJE . Double‐blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet1978;2:955‐7. ">O'Donoghue 1978</a>; <a href="./references#CD000067-bbs2-0008" title="PanésJ , López‐SanrománA , BermejoF , García‐SánchezV , EsteveM , TorresY , et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology2013;145(4):766‐74. SansM , López‐San RomainA , EsteveM , BermejoF , Garcia‐SánchezV , TorresY , et al. Early use of azathioprine has a steroid sparing effect on recently diagnosed Crohn's disease patients. Gastroenterology2012;142(5 Suppl 1):S109. ">Panes 2013</a>; <a href="./references#CD000067-bbs2-0009" title="RosenbergJL , LevinB , WallAJ , KirsnerJB . A controlled trial of azathioprine in Crohn's disease. American Journal of Digestive Diseases1975;20:721‐6. ">Rosenberg 1975</a>; <a href="./references#CD000067-bbs2-0010" title="SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology1979;77:870‐82. SummersRW , SingletonJW . National Cooperative Crohn's Disease Study (NCCDS): a controlled prospective trial of three drugs vs placebo. Gut1977;18(11):A972‐3. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77:847‐69. ">Summers 1979</a>; <a href="./references#CD000067-bbs2-0011" title="WilloughbyJM , BeckettJ , KumarPJ , DawsonAM . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2:944‐7. WilloughbyJM , KumarP , BeckettJ , DawsonAM . A double‐blind trial of azathioprine in Crohn's disease. Gut1971;12(10):864. ">Willoughby 1971</a>). Six of these trials were double‐blind and placebo‐controlled (<a href="./references#CD000067-bbs2-0001" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. CandyS , WrightJP , GerberM , AdamsG , GerigM , GoodmanR . A double blind controlled study of azathioprine in the treatment and maintenance of remission in Crohn's disease [abstract]. Gastroenterology1994;106:A659. ">Candy 1995</a>; <a href="./references#CD000067-bbs2-0003" title="ColombelJF , LemannM , BouhnikY , DuclosB , SouleJC , LereboursE , et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology2003;124(4 Suppl 1):A196‐7. LemannM , BouhnikY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. Randomized, double‐blind, placebo‐controlled, multicenter, azathioprine (AZA) withdrawal trial in Crohn’s disease (CD). Gastroenterology2002;122(4 Suppl 1):A23. LémannM , MaryJY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. A randomized, double‐blind, controlled withdrawal trial in Crohn's disease patients in long‐term remission on azathioprine. Gastroenterology2005;128(7):1812‐8. ">Lémann 2005</a>; <a href="./references#CD000067-bbs2-0007" title="O'DonoghueDP , DawsonAM , Powell‐TuckJ . Azathioprine as a maintenance treatment for Crohn's disease: a double blind withdrawal trial. Gastroenterology1978;72(5 II):1138. O'DonoghueDP , DawsonAM , Powell‐TuckJ , BownRL , Lennard‐JonesJE . Double‐blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet1978;2:955‐7. ">O'Donoghue 1978</a>; <a href="./references#CD000067-bbs2-0008" title="PanésJ , López‐SanrománA , BermejoF , García‐SánchezV , EsteveM , TorresY , et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology2013;145(4):766‐74. SansM , López‐San RomainA , EsteveM , BermejoF , Garcia‐SánchezV , TorresY , et al. Early use of azathioprine has a steroid sparing effect on recently diagnosed Crohn's disease patients. Gastroenterology2012;142(5 Suppl 1):S109. ">Panes 2013</a>; <a href="./references#CD000067-bbs2-0009" title="RosenbergJL , LevinB , WallAJ , KirsnerJB . A controlled trial of azathioprine in Crohn's disease. American Journal of Digestive Diseases1975;20:721‐6. ">Rosenberg 1975</a>; <a href="./references#CD000067-bbs2-0011" title="WilloughbyJM , BeckettJ , KumarPJ , DawsonAM . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2:944‐7. WilloughbyJM , KumarP , BeckettJ , DawsonAM . A double‐blind trial of azathioprine in Crohn's disease. Gut1971;12(10):864. ">Willoughby 1971</a>). Two of these trials were withdrawal studies, where patients who were being maintained in remission by azathioprine were randomized to continue therapy or replace their azathioprine with placebo (<a href="./references#CD000067-bbs2-0007" title="O'DonoghueDP , DawsonAM , Powell‐TuckJ . Azathioprine as a maintenance treatment for Crohn's disease: a double blind withdrawal trial. Gastroenterology1978;72(5 II):1138. O'DonoghueDP , DawsonAM , Powell‐TuckJ , BownRL , Lennard‐JonesJE . Double‐blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet1978;2:955‐7. ">O'Donoghue 1978</a>; <a href="./references#CD000067-bbs2-0003" title="ColombelJF , LemannM , BouhnikY , DuclosB , SouleJC , LereboursE , et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology2003;124(4 Suppl 1):A196‐7. LemannM , BouhnikY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. Randomized, double‐blind, placebo‐controlled, multicenter, azathioprine (AZA) withdrawal trial in Crohn’s disease (CD). Gastroenterology2002;122(4 Suppl 1):A23. LémannM , MaryJY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. A randomized, double‐blind, controlled withdrawal trial in Crohn's disease patients in long‐term remission on azathioprine. Gastroenterology2005;128(7):1812‐8. ">Lémann 2005</a>). Four trials included an induction phase on the study medication, then followed the patients that achieved remission for the maintenance phase (<a href="./references#CD000067-bbs2-0001" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. CandyS , WrightJP , GerberM , AdamsG , GerigM , GoodmanR . A double blind controlled study of azathioprine in the treatment and maintenance of remission in Crohn's disease [abstract]. Gastroenterology1994;106:A659. ">Candy 1995</a>; <a href="./references#CD000067-bbs2-0004" title="MantzarisGJ , PloyzouP , KaragiannidisA , ChristidouA , KoilakouS , TsounisD , et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid‐dependent Crohn's disease. Gastroenterology2004;126:A54. ">Mantzaris 2004</a>; <a href="./references#CD000067-bbs2-0006" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero PernoaJ , Moreno OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12:1227‐33. ">Maté‐Jiménez 2000</a>; <a href="./references#CD000067-bbs2-0010" title="SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology1979;77:870‐82. SummersRW , SingletonJW . National Cooperative Crohn's Disease Study (NCCDS): a controlled prospective trial of three drugs vs placebo. Gut1977;18(11):A972‐3. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77:847‐69. ">Summers 1979</a>). Only one trial studied 6‐mercaptopurine for maintenance of remission (<a href="./references#CD000067-bbs2-0006" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero PernoaJ , Moreno OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12:1227‐33. ">Maté‐Jiménez 2000</a>). Four studies compared azathioprine or 6‐mercaptopurine to an active therapy. <a href="./references#CD000067-bbs2-0004" title="MantzarisGJ , PloyzouP , KaragiannidisA , ChristidouA , KoilakouS , TsounisD , et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid‐dependent Crohn's disease. Gastroenterology2004;126:A54. ">Mantzaris 2004</a> compared combination therapy with azathioprine and infliximab to infliximab. <a href="./references#CD000067-bbs2-0005" title="MantzarisG , ChristidouA , SfakianakisM , RoussosA , KoilakouS , PetrakiK , et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn's disease. Inflammtory Bowel Diseases2009;15:375‐82. MantzarisGJ , PetrakiK , Chadio‐IordanidesH , ChristidouA , KaragiannidisA , GlarakisJ , et al. Maintenance therapy with azathioprine is superior to budesonide in healing endoscopic lesions and improving histology in clinically quiescent Crohn's disease. Gastroenterology2002;122(4 Suppl 1):A81. ">Mantzaris 2009</a> compared azathioprine to budesonide. <a href="./references#CD000067-bbs2-0006" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero PernoaJ , Moreno OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12:1227‐33. ">Maté‐Jiménez 2000</a> compared 6‐mercaptopurine to methotrexate and 5‐ASA. <a href="./references#CD000067-bbs2-0010" title="SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology1979;77:870‐82. SummersRW , SingletonJW . National Cooperative Crohn's Disease Study (NCCDS): a controlled prospective trial of three drugs vs placebo. Gut1977;18(11):A972‐3. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77:847‐69. ">Summers 1979</a> compared azathioprine to sulphasalazine and prednisone. <a href="./references#CD000067-bbs2-0010" title="SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology1979;77:870‐82. SummersRW , SingletonJW . National Cooperative Crohn's Disease Study (NCCDS): a controlled prospective trial of three drugs vs placebo. Gut1977;18(11):A972‐3. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77:847‐69. ">Summers 1979</a> was the only active comparator study that also included a placebo arm. The <a href="./references#CD000067-bbs2-0010" title="SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology1979;77:870‐82. SummersRW , SingletonJW . National Cooperative Crohn's Disease Study (NCCDS): a controlled prospective trial of three drugs vs placebo. Gut1977;18(11):A972‐3. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77:847‐69. ">Summers 1979</a> study also known as the National Cooperative Crohn's Disease study contained two parts. Part I had two phases. In phase one, patients with active Crohn's disease were treated with the study drug to induce remission. In phase two, patients who had achieved remission in phase one were followed to see if they maintained remission on 2.5 mg/kg/day of azathioprine. Part II included patients who had quiescent disease and patients were randomized to receive study medication to maintain remission on 1.0 mg/kg/day of azathioprine. This review includes outcome data from part one, phase two and part two. Adverse event data were reported for the entire <a href="./references#CD000067-bbs2-0010" title="SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology1979;77:870‐82. SummersRW , SingletonJW . National Cooperative Crohn's Disease Study (NCCDS): a controlled prospective trial of three drugs vs placebo. Gut1977;18(11):A972‐3. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77:847‐69. ">Summers 1979</a> study (not by phase). <a href="./references#CD000067-bbs2-0002" title="CosnesJ , BourrierA , BouhnikY , LaharieD , NahonS , BonnetJ , et al. Accelerated step‐care therapy with early azathioprine (AZA) vs. conventional step‐care therapy in Crohn's disease: a randomized study. Gastroenterology2012;142(5 Suppl 1):S161. CosnesJ , BourrierA , LaharieD , NahonS , BouhnikY , CarbonnelF , et al. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology2013;145(4):758‐65.e2; quiz e14‐5. ">Cosnes 2013</a> and <a href="./references#CD000067-bbs2-0008" title="PanésJ , López‐SanrománA , BermejoF , García‐SánchezV , EsteveM , TorresY , et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology2013;145(4):766‐74. SansM , López‐San RomainA , EsteveM , BermejoF , Garcia‐SánchezV , TorresY , et al. Early use of azathioprine has a steroid sparing effect on recently diagnosed Crohn's disease patients. Gastroenterology2012;142(5 Suppl 1):S109. ">Panes 2013</a> evaluated the effect of early administration of azathioprine in patients newly diagnosed with Crohn's disease, and included patients with active disease. <a href="./references#CD000067-bbs2-0008" title="PanésJ , López‐SanrománA , BermejoF , García‐SánchezV , EsteveM , TorresY , et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology2013;145(4):766‐74. SansM , López‐San RomainA , EsteveM , BermejoF , Garcia‐SánchezV , TorresY , et al. Early use of azathioprine has a steroid sparing effect on recently diagnosed Crohn's disease patients. Gastroenterology2012;142(5 Suppl 1):S109. ">Panes 2013</a> compared azathioprine to placebo. <a href="./references#CD000067-bbs2-0002" title="CosnesJ , BourrierA , BouhnikY , LaharieD , NahonS , BonnetJ , et al. Accelerated step‐care therapy with early azathioprine (AZA) vs. conventional step‐care therapy in Crohn's disease: a randomized study. Gastroenterology2012;142(5 Suppl 1):S161. CosnesJ , BourrierA , LaharieD , NahonS , BouhnikY , CarbonnelF , et al. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology2013;145(4):758‐65.e2; quiz e14‐5. ">Cosnes 2013</a> compared early use of azathioprine to conventional management, which could eventually include azathioprine. Both allowed patients to treat flares with steroids and still remain in the study, which was a measure of relapse in all other studies. Two studies included patients aged 15 years old or greater (<a href="./references#CD000067-bbs2-0001" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. CandyS , WrightJP , GerberM , AdamsG , GerigM , GoodmanR . A double blind controlled study of azathioprine in the treatment and maintenance of remission in Crohn's disease [abstract]. Gastroenterology1994;106:A659. ">Candy 1995</a>; <a href="./references#CD000067-bbs2-0006" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero PernoaJ , Moreno OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12:1227‐33. ">Maté‐Jiménez 2000</a>). However the majority of patients in these studies were adults. </p> <p><a href="./references#CD000067-bbs2-0001" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. CandyS , WrightJP , GerberM , AdamsG , GerigM , GoodmanR . A double blind controlled study of azathioprine in the treatment and maintenance of remission in Crohn's disease [abstract]. Gastroenterology1994;106:A659. ">Candy 1995</a> conducted a randomized, double‐blind, placebo‐controlled, trial to assess the efficacy of azathioprine in combination with prednisolone versus placebo in combination with prednisolone for induction and maintenance of remission in 63 patients with active Crohn's Disease (CDAI &gt; 200). Remission was defined as a CDAI score of &lt; 150. Patients (aged 15 to 65 years) were selected from a single site (Groot Schuur Hospital IBD Clinic). Patients were excluded from the study if they had previous surgery for Crohn's disease, symptoms suggestive of mechanical obstruction, recently received immunosuppressives, compromised hepatic function, or if they were pregnant or lactating. After one week of azathioprine 50 mg/day, the dose was held constant at 2.5 mg/kg/day for the remaining 11 weeks of phase 1, and for 12 months of phase 2 (or until the patient relapsed or withdrew from the study). In phase 1, patients (intervention group n = 33 and placebo group n = 30) received a tapering dose of prednisolone (initial dose 1 mg/kg/day tapered to 0 by week 12) in combination with azathioprine or placebo for induction of remission. Twenty out of 63 participants failed to achieve remission (7 in azathioprine group and 9 in placebo group) or withdrew from phase 1. During phase 2, patients (intervention group n = 24 and placebo group n = 19) continued to receive azathioprine or matched placebo for 12 months. The primary outcome was the proportion of patients in clinical remission. Secondary outcomes were median change in CDAI, ESR, serum CRP, serum orosomucoid concentration, and leucocyte count between the first and last visits. Differences in leucocyte count between baseline and final visit were evaluated for responders and non‐responders within the intervention group. Adverse events and compliance were also monitored. </p> <p><a href="./references#CD000067-bbs2-0002" title="CosnesJ , BourrierA , BouhnikY , LaharieD , NahonS , BonnetJ , et al. Accelerated step‐care therapy with early azathioprine (AZA) vs. conventional step‐care therapy in Crohn's disease: a randomized study. Gastroenterology2012;142(5 Suppl 1):S161. CosnesJ , BourrierA , LaharieD , NahonS , BouhnikY , CarbonnelF , et al. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology2013;145(4):758‐65.e2; quiz e14‐5. ">Cosnes 2013</a> performed a three‐year trial to evaluate the efficacy of early azathioprine treatment within six months of diagnosis versus conventional management of Crohn's disease patients with a high risk of disabling disease. Remission was defined as a trimester spent free of: flare, treatment with steroids or anti‐TNF‐alpha antagonists, active perianal disease (pain or discharge with induration, skin tags, ulceration, fissure or fistula), Crohn's disease‐related hospitalization (including those caused by drug side effects); or surgery. The study was performed at 24 French centres and was a randomized, parallel group, open‐label trial. Patients were at least 18 years of age (N = 147; intervention n= 72); and were classified as high risk if they had been diagnosed when they were under 40 years of age, had received corticosteroids within three months of diagnosis or had active perianal lesions. Patients were excluded if they had previous treatment with immunomodulators or anti–TNF‐alpha therapy; immediate need for surgery or anti‐TNF‐alpha therapy; severe comorbidity; documented infection; renal or liver failure; contraindication to thiopurines according to labelling recommendations; malignancy; history of drug abuse; predictable poor compliance; or if they were pregnant. The primary outcome was the proportion of trimesters spent in remission. The secondary outcomes were the proportion of trimesters in the three year trial period that contain any of the above listed failures of remission; duration of significant corticosteroid exposure per trimester; total exposures (in milligrams) of prednisone and budesonide per trimester; time to first perianal surgery, first intestinal resection, and first anti‐TNF use; median CDAI scores and C‐reactive protein concentrations throughout follow‐up; quality of life (measured by the IBD Questionnaire) at months 12, 24, and 36; total number of days of hospitalization; and total number of days out of work per trimester. Safety data and adverse events were also collected. </p> <p><a href="./references#CD000067-bbs2-0003" title="ColombelJF , LemannM , BouhnikY , DuclosB , SouleJC , LereboursE , et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology2003;124(4 Suppl 1):A196‐7. LemannM , BouhnikY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. Randomized, double‐blind, placebo‐controlled, multicenter, azathioprine (AZA) withdrawal trial in Crohn’s disease (CD). Gastroenterology2002;122(4 Suppl 1):A23. LémannM , MaryJY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. A randomized, double‐blind, controlled withdrawal trial in Crohn's disease patients in long‐term remission on azathioprine. Gastroenterology2005;128(7):1812‐8. ">Lémann 2005</a> conducted a randomized, double‐blind, placebo‐controlled trial at 11 French sites and 1 Belgian site. The study evaluated the effectiveness of azathioprine for long term remission of Crohn's disease. Patients were monitored for relapse, (defined as CDAI &gt; 250 or CDAI of 150‐250 on 3 consecutive weeks plus an increase of ≥ 75 points above baseline score, or the need for surgery (except limited perianal surgery)). Patients selected for the study (N = 83, azathioprine group, n = 40) were at least 18 years of age, and had continuous azathioprine treatment for a minimum of 42 months during which they did not experience a flare‐up, receive oral prednisone (&gt;10 mg/day) budesonide or another immunosuppressive or biological agent; ingest artificial nutrition; undergo surgery (except limited perianal surgery). Patients were excluded if they had active disease (CDAI &gt; 150 at entry), disease was limited to the perianal area, or if they had received azathioprine to prevent postoperative recurrence after curative surgical resection. Adverse events were also monitored. </p> <p><a href="./references#CD000067-bbs2-0004" title="MantzarisGJ , PloyzouP , KaragiannidisA , ChristidouA , KoilakouS , TsounisD , et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid‐dependent Crohn's disease. Gastroenterology2004;126:A54. ">Mantzaris 2004</a> conducted a randomized, phase II study that evaluated the effectiveness of azathioprine combined with infliximab compared to infliximab monotherapy. Patients (N = 47) were between ages 18 and 57 with active, steroid‐resistant Crohn's disease (CDAI &gt; 150). Patients were ineligible if they had fistulizing or fibrostenotic disease, septic complications, or if they had not received previous treatment with immunomodulators. After a six week induction phase, patients in remission continued their assigned therapies. All patients received either infliximab (5 mg/kg every 8 weeks) or infliximab and azathioprine (2.5 mg/kg/day). The primary outcome was the proportion of patients with maintenance of remission. Adverse effects were also monitored. The study was published as an abstract. </p> <p><a href="./references#CD000067-bbs2-0005" title="MantzarisG , ChristidouA , SfakianakisM , RoussosA , KoilakouS , PetrakiK , et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn's disease. Inflammtory Bowel Diseases2009;15:375‐82. MantzarisGJ , PetrakiK , Chadio‐IordanidesH , ChristidouA , KaragiannidisA , GlarakisJ , et al. Maintenance therapy with azathioprine is superior to budesonide in healing endoscopic lesions and improving histology in clinically quiescent Crohn's disease. Gastroenterology2002;122(4 Suppl 1):A81. ">Mantzaris 2009</a> compared the effectiveness of azathioprine (2 to 2.5 mg/kg/day) to budesonide (6 to 9 mg/day) for maintenance of remission in patients (aged 18‐67 years) with steroid‐dependant Crohn's disease (CDAI &lt; 150) over a one year period, which was extended to 18 months for those maintaining remission at the one year cutoff. Steroid‐dependency was described as individuals having at least one flare in the previous six to twelve months which had been successfully treated with steroids, but returned during steroid tapering or after steroid withdrawal. Included patients had recently flared (within one month of study inclusion) and were receiving a tapered dose of oral prednisolone for at least one month prior to randomization. The primary outcomes were mucosal healing and histological remission. Secondary outcomes included annual relapse rate, time in remission, discontinuation of study medications, changes in CDAI or health‐related quality of life, and safety data. Compliance and the use of any other medications were also monitored. </p> <p><a href="./references#CD000067-bbs2-0006" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero PernoaJ , Moreno OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12:1227‐33. ">Maté‐Jiménez 2000</a> conducted a 106 week, single‐centre, randomized three arm two phase trial with sub‐stratification for ulcerative colitis (n = 34) and Crohn's disease (n = 38). The induction phase was 30 weeks, and was followed by a maintenance phase for 76 weeks to evaluate the efficacy of adding either 6‐mercaptopurine, methotrexate or 5‐aminosalicylic acid to prednisone to induce remission (phase one) and then maintain remission without prednisone (phase two). Patients selected for inclusion (N = 72) were aged 15 to 70 years with steroid‐dependent, radiologically or endoscopically confirmed inflammatory bowel disease from Digestive DIseases Service, Hospital de la Princesa, who had been followed for at least one year and had never previously received either 6‐mercaptopurine or methotrexate. Steroid dependence was defined as patients who could not be weaned off less than 20 mg prednisone without induction of inflammatory activity, and a CDAI &gt; 200. Exclusion criteria included: patients over the age of 70 years or under the age of 15 years; no signed consent; those with clinically significant cardiac, hepatic or renal disease; ongoing bacterial infection; pregnancy; lactating or not using reliable contraceptive techniques; patients using concomitant allopurinol, NSAIDs, tetracyclines or phenytoin in significant doses; those who have had extensive surgery for their Crohn's disease; or those who have symptoms that suggest a potential need for urgent surgery. The induction phase used the individualized dose of prednisone used prior to study inclusion as the starting dose (highest was 1 mg/kg/day prednisone) to be tapered by 8 mg/kg/day prednisone over the 30 weeks to 0 and the following therapies under study, 6‐mercaptopurine 1.5mg/kg/day (group A, n = 16 with Crohn's), methotrexate, 15 mg/week (group B, n = 15 with Crohn's) or 5‐aminosalicyclic acid, 3 g/day (group C, n = 7 with Crohn's). For the maintenance phase, only those who achieved remission after stopping prednisone during the induction phase were included in this portion of the study. In these patients the methotrexate dose was reduced to 10 mg/week and the 6‐mercaptopurine dose reduced to 1 mg/kg/day. The 5‐aminosalicylic acid dose used for maintenance therapy did not change (3g/day). No other medications, except antidiarrhoeals and supplements, were allowed. The primary outcome for phase one was induction of remission and cessation of steroids, while phase 2 was clinical remission. "Relapse was defined as CDAI &gt; 150 and orosomucoid &gt; 100 (N 88 mg/dl) with no response to 6 g daily of 5‐aminosalicylic acid and with need of prednisone therapy in Crohn's disease patients." Adverse events were a secondary outcome. </p> <p><a href="./references#CD000067-bbs2-0007" title="O'DonoghueDP , DawsonAM , Powell‐TuckJ . Azathioprine as a maintenance treatment for Crohn's disease: a double blind withdrawal trial. Gastroenterology1978;72(5 II):1138. O'DonoghueDP , DawsonAM , Powell‐TuckJ , BownRL , Lennard‐JonesJE . Double‐blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet1978;2:955‐7. ">O'Donoghue 1978</a> performed a randomized, double‐blind, placebo‐controlled, 52 week, withdrawal study, which initially sub‐stratified participants into those only on azathioprine and those also on other anti‐inflammatories and azathioprine. The study evaluated the efficacy of azathioprine for maintenance of remission, defined as preventing relapse ("significant deterioration in clinical state requiring a change in treatment as judged by two doctors unaware of the patient's treatment"), in patients (N = 51) with quiescent Crohn's disease taking azathioprine (2 mg/kg/day) for at least six months prior to study inclusion. Patients receiving azathioprine combined with sulphasalazine or low dose corticosteroids were included; this treatment remained unchanged throughout study period. Patients were also allowed medications for symptom control and supplements. Patients were monitored for primary outcomes using a modified DAS scoring system completed at each clinical assessment. Adverse events and serious adverse events were also monitored; one patient died during the study. </p> <p><a href="./references#CD000067-bbs2-0008" title="PanésJ , López‐SanrománA , BermejoF , García‐SánchezV , EsteveM , TorresY , et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology2013;145(4):766‐74. SansM , López‐San RomainA , EsteveM , BermejoF , Garcia‐SánchezV , TorresY , et al. Early use of azathioprine has a steroid sparing effect on recently diagnosed Crohn's disease patients. Gastroenterology2012;142(5 Suppl 1):S109. ">Panes 2013</a> conducted a randomized, multi‐centre, double‐blind, placebo‐controlled study over 76 weeks in 31 Spanish hospitals. The study evaluated the efficacy of early administration of azathioprine (2.5 mg/kg/day) in patients with newly diagnosed (&lt; 8 weeks) Crohn's disease for maintenance of corticosteroid‐free clinical remission. Sustained corticosteroid‐free remission was defined as the presence of clinical remission (CDAI score &lt; 150 at each visit) in patients who had not been treated with corticosteroids during the entire study or patients who were treated with corticosteroids at baseline after the scheduled weaning of this treatment. Patients (N= 131; azathioprine, n = 68) aged 18 to 70 years, diagnosed with established Crohn's disease criteria within 8 weeks of screening, "irrespective of disease activity and use of corticosteroids at the time of screening." Exclusion criteria included previous treatment with azathioprine, 6‐mercaptopurine, methotrexate, cyclosporin, tacrolimus, mycophenolate mofetil, infliximab or adalimumab; patients with an immediate need for surgery or patients who had surgery for Crohn's disease; penetrating disease, symptomatic stenosis, perianal fistulas; patients with severe co‐morbidities, documented infection, malignancy, history of drug use; or those who were pregnant. Corticosteroids were allowed to treat flares during the study, (prednisone doses ranged 1 mg/kg/day to a maximum of 60 mg/day; budesonide dosage 9 mg/day), but were tapered using a predetermined schedule. No other medications used to treat Crohn's disease were allowed, except antibiotics for suspected or demonstrated infection. Secondary outcomes included relapse‐free survival, mean CDAI and IBDQ scores, and CRP concentrations at each visit; requirement for corticosteroids; cumulative dose of corticosteroids; development of a fistula; hospitalization; and CD‐related surgery and cumulative prednisone dose. Safety data were also collected. </p> <p><a href="./references#CD000067-bbs2-0009" title="RosenbergJL , LevinB , WallAJ , KirsnerJB . A controlled trial of azathioprine in Crohn's disease. American Journal of Digestive Diseases1975;20:721‐6. ">Rosenberg 1975</a> conducted a randomized, double‐blind, identically matched placebo‐controlled trial over 26 weeks that evaluated the effect of azathioprine (2.0 mg/kg/day) on reducing the need for steroids in patients &gt; 16 years of age with Crohn's disease who required daily prednisone (minimum dose 10 mg) for symptom control for at least 12 weeks prior to study inclusion (N = 20). Patients were excluded if they had advanced hepatic or renal disease, wished to become pregnant within the study time frame, or were likely to require surgery. The primary outcome was a reduction of prednisone usage over the trial. Prednisone was tapered according to a predetermined schedule when the patient met all of the following criteria: "3 or fewer bowel movements a day, absent to mild pain and malaise, weight loss less than 2 kg, and fever (&gt; 37.5ºC) less than one fourth of the time". Prednisone was increased by 10 mg/day if a patient had &gt; 6 bowel movements per day, severe pain or malaise, &gt; 3 kg weight loss or fever (&gt; 37.5ºC) for greater than half the time over seven days. If the patients condition did not change, the prednisone dosage remained constant. Patients were allowed to continue any other medications prescribed prior to study inclusion. Safety data were also collected. </p> <p><a href="./references#CD000067-bbs2-0010" title="SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology1979;77:870‐82. SummersRW , SingletonJW . National Cooperative Crohn's Disease Study (NCCDS): a controlled prospective trial of three drugs vs placebo. Gut1977;18(11):A972‐3. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77:847‐69. ">Summers 1979</a> conducted two independent trials at the same time to evaluate the efficacy of sulphasalazine, prednisone, and azathioprine against placebo for inducing and maintaining remission in patients with active Crohn's disease (CDAI &gt; 150 with radiologic findings of disease, Part 1, phase 1 and 2) and at maintaining remission in patients already in remission (either medically‐ or surgically‐induced) (Part 2). The studies were randomized, double‐blind, placebo‐controlled trials with patients from 14 centres. Part one was a two phase study, with the first phase (N = 295, placebo n = 77; sulphasalazine n = 74; prednisone n = 85; azathioprine n = 59) inducing remission over 17 weeks using the following identically matched medications and placebo: prednisone: 0.25 mg/kg/day if CDAI &lt; 150; 0.5 mg/kg/day if CDAI = 150 to 300; 0.75 mg/kg/day if CDAI &gt; 300; sulphasalazine: 1 g/15 kg/day; azathioprine: 2.5 mg/kg/day, or placebo. Patients who achieved remission in phase one entered phase two for one to two years of maintenance treatment. These 86 patients included 20 in the placebo group, 19 in the sulphasalazine group, 28 in the prednisone group and 19 in the azathioprine group. Part 2 evaluated maintenance of remission in 226 patients who achieved clinical remission in the previous 2 years or 48 who had undergone complete surgical resection of all diseased bowel within a year of entry. Part 2 included 274 patients: 101 received placebo, 58 received sulphasalazine, 61 received placebo and 54 received azathioprine. Both studies were also sub‐stratified by disease sites, prior steroid usage and disease activity. Safety data were collected throughout both phases. </p> <p><a href="./references#CD000067-bbs2-0011" title="WilloughbyJM , BeckettJ , KumarPJ , DawsonAM . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2:944‐7. WilloughbyJM , KumarP , BeckettJ , DawsonAM . A double‐blind trial of azathioprine in Crohn's disease. Gut1971;12(10):864. ">Willoughby 1971</a> performed a 22 patient, randomized, double‐blind, placebo‐controlled study to evaluate the effect that azathioprine has on maintaining remission of Crohn's disease once it has been induced by prednisolone alone or combined with azathioprine. This was completed using two groups of patients, randomizing each to azathioprine or placebo. Group 1 (n = 12, azathioprine n = 6) consisted of patients with first time attacks or relapses of moderate to severe severity not treated with steroids in the previous 3 months, while group 2 (n= 10, azathioprine n =5) studied outpatients maintained on long term prednisolone (7.5 to 15 mg/day) for 5 to 72 months. The first group received prednisolone (initial dose 60 mg/day) until remission was achieved; it was then tapered on a 3‐week schedule to 10 mg and discontinued after hospital discharge if remission was maintained. Azathioprine was prescribed at 4.0 mg/kg/day for the first 10 days and then at 2.0 mg/kg/day until the end of 24 weeks. The second group received 2.0 mg/kg/day azathioprine or placebo and maintained their pre‐study dose of prednisolone for "at least 4 weeks after prednisolone was reduced as for group 1." Participants were also prescribed prochlorperazine for nausea and codeine phosphate was continued if the patient received it prior to study entry. Disease activity was monitored using DAS and relapse was considered the return of previous symptoms. </p> </section> <section id="CD000067-sec-0042"> <h4 class="title">Excluded studies</h4> <p>Twenty‐seven studies were excluded for various reasons. Nine studies were excluded because they evaluated post‐operative maintenance of remission (<a href="./references#CD000067-bbs2-0012" title="AbdelliMN , Ben AbdallahH , HouissaF , BoualiMR , KhediriMF . Azathioprine for prevention of postoperative recurrence in Crohn's disease. Tunisie Médicale2007;85:569‐72. ">Abdelli 2007</a>; <a href="./references#CD000067-bbs2-0013" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease.. Gastroenterology2004;127:730‐40. ">Ardizzone 2004</a>; <a href="./references#CD000067-bbs2-0014" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a>; <a href="./references#CD000067-bbs2-0018" title="D'HaensG , VermeireS , VanAsscheG , NomanM . Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn’s disease: a controlled randomized trial. Gastroenterology2008;135(4):1123–29. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , WermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: a double‐blind controlled randomized trial. Gastroenterology2007;132(4 Suppl 2):A52. ">D'Haens 2008b</a>; <a href="./references#CD000067-bbs2-0020" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine, or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. ">Hanauer 2004a</a>; <a href="./references#CD000067-bbs2-0021" title="HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn's disease. Gastroenterology2006;130(4 Suppl 2):A480. ">Herfarth 2006</a>; <a href="./references#CD000067-bbs2-0027" title="NosP , HinojosaJ , AguileraV , MolesJR , PastorM , PonceJ , et al. Azathioprine and 5‐ASA in the prevention of postoperative recurrence of Crohn's disease. Gastroenterología y Hepatología2000;23:374‐8. ">Nos 2000</a>; <a href="./references#CD000067-bbs2-0031" title="ReinischW , AngelbergerS , HerrlingerK , ShonovaO , LukasS , Bar‐MeirS , et al. A double‐blind, double‐dummy, randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A‐70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double‐blind, double‐dummy, multicentre trial. Gut2010;59:752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ">Reinisch 2010</a>; <a href="./references#CD000067-bbs2-0033" title="SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. The American journal of gastroenterology2013;108(11):1731‐42. ">Savarino 2013</a>). Six studies were excluded because they were not randomized controlled trials (<a href="./references#CD000067-bbs2-0012" title="AbdelliMN , Ben AbdallahH , HouissaF , BoualiMR , KhediriMF . Azathioprine for prevention of postoperative recurrence in Crohn's disease. Tunisie Médicale2007;85:569‐72. ">Abdelli 2007</a>; <a href="./references#CD000067-bbs2-0015" title="ChebliJM , GaburriPD , DeSouzaAF , PintoAL , ChebliLA , FelgaGE , et al. Long‐term results with azathioprine therapy in patients with corticosteroid‐dependent Crohn's disease: open‐label prospective study. Journal of Gastroenterology and Hepatology2007;22:268‐74. ">Chebli 2007</a>; <a href="./references#CD000067-bbs2-0023" title="KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo in Crohn’s Disease: a 2 year multicenter trial. Gastroenterology1998;114(4 Pt 2):A‐486. ">Korelitz 1998</a>; <a href="./references#CD000067-bbs2-0026" title="MantzarisGJ , RoussosA , ChristidouA , KoilakouS , KalantzisCN , PetrakiK , et al. The long‐term efficacy of azathioprine does not wane after four years of continuous treatment in patients with steroid‐dependent luminal Crohn's disease. Journal of Crohn's and Colitis2007;1(1):28‐34. ">Mantzaris 2007</a>; <a href="./references#CD000067-bbs2-0027" title="NosP , HinojosaJ , AguileraV , MolesJR , PastorM , PonceJ , et al. Azathioprine and 5‐ASA in the prevention of postoperative recurrence of Crohn's disease. Gastroenterología y Hepatología2000;23:374‐8. ">Nos 2000</a>; <a href="./references#CD000067-bbs2-0034" title="TretonX , BouhnikY , MaryJ , ColombelJ , DuclosB , SouleJ , et al. Azathioprine withdrawal in patients with Crohn's disease (CD) maintained on prolonged remission under treatment is associated with a high risk of relapse. Gastroenterology2004;126(4 Suppl 2):A113. TretonX , BouhnikY , MaryJ , ColombelJ , DuclosB , SouleJ , et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clinical Gastroenterology and Hepatology2009;7(1):80‐5. ">Treton 2009</a>). Six studies were excluded because the patients had active disease (<a href="./references#CD000067-bbs2-0016" title="ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ">Colombel 2010</a>; <a href="./references#CD000067-bbs2-0019" title="deSouzaGS , VidigalFM , ChebliLA , daRocha RibeiroTC , FurtadoMC , deLima PaceFH , et al. Effect of azathioprine or mesalazine therapy on incidence of re‐hospitalization in sub‐occlusive ileocecal Crohn's disease patients. Medical Science Monitor2013;19:716‐22. ">de Souza 2013</a>; <a href="./references#CD000067-bbs2-0022" title="KleinM , BinderHJ , MitchellM , AaronsonR , SpiroH . Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology1974;66(5):916‐22. ">Klein 1974</a>; <a href="./references#CD000067-bbs2-0028" title="OrenR , MoshkowitzM , OdesS , BeckerS , KeterD , PomeranzI , et al. Methotrexate in chronic active Crohn's disease: a double‐blind, randomized, Israeli multicenter trial. American Journal of Gastroenterology1997;92(12):2203‐9. ">Oren 1997</a>; <a href="./references#CD000067-bbs2-0029" title="PresentDH , KorelitzBI , WischN . Treatment of Crohn's disease with 6‐mercatopurine ‐ a long‐term, randomized, double‐blind study. Innere Medizin1980;7(4):147‐8. PresentDH , KorelitzBI , WischN , GlassJL , SacharDB , PasternackBS . Treatment of Crohn's disease with 6‐mercaptopurine. A long‐term, randomized, double‐blind study. New England Journal of Medicine1980;302(18):981‐7. ">Present 1980</a>; <a href="./references#CD000067-bbs2-0030" title="ReinischW , PanésJ , LémannM , SchreiberS , FeaganB , SchmidtS , et al. A multicenter, randomized, double‐blind trial of everolimus versus azathioprine and placebo to maintain steroid‐induced remission in patients with moderate‐to‐severe active Crohn's disease. American Journal of Gastroenterology2008;103:2284‐93. ">Reinisch 2008</a>). Three studies were excluded because all of the patients received azathioprine (<a href="./references#CD000067-bbs2-0017" title="D’HaensG , BaertF , vanAsscheG , CaenepeelP , VergauweP , TuynmanH , et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet2008;371:660‐7. ">D'Haens 2008a</a>; <a href="./references#CD000067-bbs2-0024" title="LémannM , MaryJY , DuclosB , VeyracM , DupasJL , DelchierJC , et al. Infliximab plus azathioprine for steroid‐dependent Crohn’s disease patients: a randomized placebo‐controlled trial. Gastroenterology2006;130:1054‐61. ">Lémann 2006</a>; <a href="./references#CD000067-bbs2-0025" title="ManosaM , CabreE , BernalI , EsteveM , Garcia‐PlanellaE , RicartE , et al. Addition of metronidazole to azathioprine for the prevention of postoperative recurrence of Crohn's disease: a randomized, double‐blind, placebo‐controlled trial. Inflammatory Bowel Diseases2013;19(9):1889‐95. ManosaM , CabreE , BernalI , EsteveM , Garcia‐PlanellaE , RicartE , et al. Azathioprine versus azathioprine plus metronidazole for the prevention of postoperative endoscopic recurrence of Crohn's disease: a randomized, placebo‐controlled trial. Journal of Crohn's and Colitis2012;6:S93. ">Manosa 2013</a>). <a href="./references#CD000067-bbs2-0032" title="RhodesJ , BaintonD , BeckP . Azathioprine in Crohn's disease. Lancet1970;2(7683):1142. RhodesJ , BaintonD , BeckP , CampbellH . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2(7737):1273‐6. ">Rhodes 1971</a> was excluded as it was a cross‐over study that failed to provide analysis before the first cross‐over. Another study did not specify the type of immunosuppressant that was studied (<a href="./references#CD000067-bbs2-0035" title="vanAsscheG , Magdelaine‐BeuzelinC , D'HaensG , BaertF , NomanM , VermeireS , et al. Withdrawal of immunosuppression in crohn’s disease treated with scheduled infliximab maintenance: A randomized trial. Gastroenterology2008;134(7):1861‐8. ">van Assche 2008</a>). <a href="./references#CD000067-bbs2-0036" title="VilienM , DahlerupJF , MunckLK , NorregaardP , GronbaekK , FalligborgJ . Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following year. Alimentary Pharmacology and Therapeutics2004;19(11):1147‐52. ">Vilien 2004</a> was excluded because the control group did not receive any treatment. The <a href="./references#CD000067-bbs2-0037" title="WatsonWC , BukosdkyM . Azathioprine in management of Crohn's disease: a randomized cross‐over study. Gastroenterology1974;66:796. ">Watson 1979</a> study was a randomized, double‐blind placebo‐controlled cross‐over study of azathioprine maintenance therapy which was never published as a full paper. <a href="./references#CD000067-bbs2-0038" title="WilloughbyJM , ThomasJM , SudweeksDM . Azathioprine and levamisole in Crohn's disease: a double blind controlled trial of one year's treatment with long follow up. Gut1990;31(Suppl 10):A1193. ">Willoughby 1990</a> was a randomized trial comparing azathioprine with levamisole. This study did not report any of our pre‐specified outcome variables. </p> <p>Excluded studies and justification for exclusion are reported in the <a href="./references#CD000067-sec-0067" title="">Characteristics of excluded studies</a> tables. </p> </section> </section> <section id="CD000067-sec-0043"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias for included studies in summarized <a href="#CD000067-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD000067-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD000067-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD000067-sec-0044"> <h4 class="title">Allocation</h4> <p>The method of randomization was described in four studies (<a href="./references#CD000067-bbs2-0002" title="CosnesJ , BourrierA , BouhnikY , LaharieD , NahonS , BonnetJ , et al. Accelerated step‐care therapy with early azathioprine (AZA) vs. conventional step‐care therapy in Crohn's disease: a randomized study. Gastroenterology2012;142(5 Suppl 1):S161. CosnesJ , BourrierA , LaharieD , NahonS , BouhnikY , CarbonnelF , et al. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology2013;145(4):758‐65.e2; quiz e14‐5. ">Cosnes 2013</a>; <a href="./references#CD000067-bbs2-0004" title="MantzarisGJ , PloyzouP , KaragiannidisA , ChristidouA , KoilakouS , TsounisD , et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid‐dependent Crohn's disease. Gastroenterology2004;126:A54. ">Mantzaris 2004</a>; <a href="./references#CD000067-bbs2-0005" title="MantzarisG , ChristidouA , SfakianakisM , RoussosA , KoilakouS , PetrakiK , et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn's disease. Inflammtory Bowel Diseases2009;15:375‐82. MantzarisGJ , PetrakiK , Chadio‐IordanidesH , ChristidouA , KaragiannidisA , GlarakisJ , et al. Maintenance therapy with azathioprine is superior to budesonide in healing endoscopic lesions and improving histology in clinically quiescent Crohn's disease. Gastroenterology2002;122(4 Suppl 1):A81. ">Mantzaris 2009</a>; <a href="./references#CD000067-bbs2-0008" title="PanésJ , López‐SanrománA , BermejoF , García‐SánchezV , EsteveM , TorresY , et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology2013;145(4):766‐74. SansM , López‐San RomainA , EsteveM , BermejoF , Garcia‐SánchezV , TorresY , et al. Early use of azathioprine has a steroid sparing effect on recently diagnosed Crohn's disease patients. Gastroenterology2012;142(5 Suppl 1):S109. ">Panes 2013</a>), which received a low risk of bias assessment. The remainder of the studies were judged to have an unclear risk of bias for this item. The methods used for allocation concealment were adequately described in six studies (<a href="./references#CD000067-bbs2-0002" title="CosnesJ , BourrierA , BouhnikY , LaharieD , NahonS , BonnetJ , et al. Accelerated step‐care therapy with early azathioprine (AZA) vs. conventional step‐care therapy in Crohn's disease: a randomized study. Gastroenterology2012;142(5 Suppl 1):S161. CosnesJ , BourrierA , LaharieD , NahonS , BouhnikY , CarbonnelF , et al. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology2013;145(4):758‐65.e2; quiz e14‐5. ">Cosnes 2013</a>; <a href="./references#CD000067-bbs2-0003" title="ColombelJF , LemannM , BouhnikY , DuclosB , SouleJC , LereboursE , et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology2003;124(4 Suppl 1):A196‐7. LemannM , BouhnikY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. Randomized, double‐blind, placebo‐controlled, multicenter, azathioprine (AZA) withdrawal trial in Crohn’s disease (CD). Gastroenterology2002;122(4 Suppl 1):A23. LémannM , MaryJY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. A randomized, double‐blind, controlled withdrawal trial in Crohn's disease patients in long‐term remission on azathioprine. Gastroenterology2005;128(7):1812‐8. ">Lémann 2005</a>; <a href="./references#CD000067-bbs2-0004" title="MantzarisGJ , PloyzouP , KaragiannidisA , ChristidouA , KoilakouS , TsounisD , et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid‐dependent Crohn's disease. Gastroenterology2004;126:A54. ">Mantzaris 2004</a>; <a href="./references#CD000067-bbs2-0008" title="PanésJ , López‐SanrománA , BermejoF , García‐SánchezV , EsteveM , TorresY , et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology2013;145(4):766‐74. SansM , López‐San RomainA , EsteveM , BermejoF , Garcia‐SánchezV , TorresY , et al. Early use of azathioprine has a steroid sparing effect on recently diagnosed Crohn's disease patients. Gastroenterology2012;142(5 Suppl 1):S109. ">Panes 2013</a>; <a href="./references#CD000067-bbs2-0009" title="RosenbergJL , LevinB , WallAJ , KirsnerJB . A controlled trial of azathioprine in Crohn's disease. American Journal of Digestive Diseases1975;20:721‐6. ">Rosenberg 1975</a>; <a href="./references#CD000067-bbs2-0010" title="SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology1979;77:870‐82. SummersRW , SingletonJW . National Cooperative Crohn's Disease Study (NCCDS): a controlled prospective trial of three drugs vs placebo. Gut1977;18(11):A972‐3. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77:847‐69. ">Summers 1979</a>). The other six studies were assessed as having an unclear risk of bias with regard to allocation concealment. </p> </section> <section id="CD000067-sec-0045"> <h4 class="title">Blinding</h4> <p>Six studies described adequate methods for blinding, including who was blinded and how blinding was maintained and these studies were rated as low risk of bias for blinding (<a href="./references#CD000067-bbs2-0001" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. CandyS , WrightJP , GerberM , AdamsG , GerigM , GoodmanR . A double blind controlled study of azathioprine in the treatment and maintenance of remission in Crohn's disease [abstract]. Gastroenterology1994;106:A659. ">Candy 1995</a>; <a href="./references#CD000067-bbs2-0003" title="ColombelJF , LemannM , BouhnikY , DuclosB , SouleJC , LereboursE , et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology2003;124(4 Suppl 1):A196‐7. LemannM , BouhnikY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. Randomized, double‐blind, placebo‐controlled, multicenter, azathioprine (AZA) withdrawal trial in Crohn’s disease (CD). Gastroenterology2002;122(4 Suppl 1):A23. LémannM , MaryJY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. A randomized, double‐blind, controlled withdrawal trial in Crohn's disease patients in long‐term remission on azathioprine. Gastroenterology2005;128(7):1812‐8. ">Lémann 2005</a>; <a href="./references#CD000067-bbs2-0008" title="PanésJ , López‐SanrománA , BermejoF , García‐SánchezV , EsteveM , TorresY , et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology2013;145(4):766‐74. SansM , López‐San RomainA , EsteveM , BermejoF , Garcia‐SánchezV , TorresY , et al. Early use of azathioprine has a steroid sparing effect on recently diagnosed Crohn's disease patients. Gastroenterology2012;142(5 Suppl 1):S109. ">Panes 2013</a>; <a href="./references#CD000067-bbs2-0009" title="RosenbergJL , LevinB , WallAJ , KirsnerJB . A controlled trial of azathioprine in Crohn's disease. American Journal of Digestive Diseases1975;20:721‐6. ">Rosenberg 1975</a>; <a href="./references#CD000067-bbs2-0010" title="SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology1979;77:870‐82. SummersRW , SingletonJW . National Cooperative Crohn's Disease Study (NCCDS): a controlled prospective trial of three drugs vs placebo. Gut1977;18(11):A972‐3. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77:847‐69. ">Summers 1979</a>; <a href="./references#CD000067-bbs2-0011" title="WilloughbyJM , BeckettJ , KumarPJ , DawsonAM . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2:944‐7. WilloughbyJM , KumarP , BeckettJ , DawsonAM . A double‐blind trial of azathioprine in Crohn's disease. Gut1971;12(10):864. ">Willoughby 1971</a>). Three of the trials were open label (<a href="./references#CD000067-bbs2-0002" title="CosnesJ , BourrierA , BouhnikY , LaharieD , NahonS , BonnetJ , et al. Accelerated step‐care therapy with early azathioprine (AZA) vs. conventional step‐care therapy in Crohn's disease: a randomized study. Gastroenterology2012;142(5 Suppl 1):S161. CosnesJ , BourrierA , LaharieD , NahonS , BouhnikY , CarbonnelF , et al. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology2013;145(4):758‐65.e2; quiz e14‐5. ">Cosnes 2013</a>; <a href="./references#CD000067-bbs2-0005" title="MantzarisG , ChristidouA , SfakianakisM , RoussosA , KoilakouS , PetrakiK , et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn's disease. Inflammtory Bowel Diseases2009;15:375‐82. MantzarisGJ , PetrakiK , Chadio‐IordanidesH , ChristidouA , KaragiannidisA , GlarakisJ , et al. Maintenance therapy with azathioprine is superior to budesonide in healing endoscopic lesions and improving histology in clinically quiescent Crohn's disease. Gastroenterology2002;122(4 Suppl 1):A81. ">Mantzaris 2009</a>; <a href="./references#CD000067-bbs2-0006" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero PernoaJ , Moreno OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12:1227‐33. ">Maté‐Jiménez 2000</a>), and thus rated as high risk of bias for blinding. <a href="./references#CD000067-bbs2-0004" title="MantzarisGJ , PloyzouP , KaragiannidisA , ChristidouA , KoilakouS , TsounisD , et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid‐dependent Crohn's disease. Gastroenterology2004;126:A54. ">Mantzaris 2004</a> was single‐blind. All assessors were blind to treatment assignment. <a href="./references#CD000067-bbs2-0007" title="O'DonoghueDP , DawsonAM , Powell‐TuckJ . Azathioprine as a maintenance treatment for Crohn's disease: a double blind withdrawal trial. Gastroenterology1978;72(5 II):1138. O'DonoghueDP , DawsonAM , Powell‐TuckJ , BownRL , Lennard‐JonesJE . Double‐blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet1978;2:955‐7. ">O'Donoghue 1978</a> did not describe blinding. </p> </section> <section id="CD000067-sec-0046"> <h4 class="title">Incomplete outcome data</h4> <p>As a result of some missing data being only vaguely justified or not discussed two studies received an unclear risk of bias assessment for incomplete outcome data (<a href="./references#CD000067-bbs2-0010" title="SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology1979;77:870‐82. SummersRW , SingletonJW . National Cooperative Crohn's Disease Study (NCCDS): a controlled prospective trial of three drugs vs placebo. Gut1977;18(11):A972‐3. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77:847‐69. ">Summers 1979</a>; <a href="./references#CD000067-bbs2-0011" title="WilloughbyJM , BeckettJ , KumarPJ , DawsonAM . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2:944‐7. WilloughbyJM , KumarP , BeckettJ , DawsonAM . A double‐blind trial of azathioprine in Crohn's disease. Gut1971;12(10):864. ">Willoughby 1971</a>), while the remaining studies were determined to be a low risk for attrition bias. </p> </section> <section id="CD000067-sec-0047"> <h4 class="title">Selective reporting</h4> <p>One study performed <i>post hoc</i> analyses that were not described in the methods section and this study was rated as unclear risk of bias for selective reporting (<a href="./references#CD000067-bbs2-0006" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero PernoaJ , Moreno OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12:1227‐33. ">Maté‐Jiménez 2000</a>). <a href="./references#CD000067-bbs2-0008" title="PanésJ , López‐SanrománA , BermejoF , García‐SánchezV , EsteveM , TorresY , et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology2013;145(4):766‐74. SansM , López‐San RomainA , EsteveM , BermejoF , Garcia‐SánchezV , TorresY , et al. Early use of azathioprine has a steroid sparing effect on recently diagnosed Crohn's disease patients. Gastroenterology2012;142(5 Suppl 1):S109. ">Panes 2013</a> reported on all pre‐specified primary and secondary outcomes and a <i>post hoc</i> analysis. However, the authors clearly indicated that they were reporting a <i>post hoc</i> analysis so we rated the study as low risk of bias for selective reporting. <a href="./references#CD000067-bbs2-0004" title="MantzarisGJ , PloyzouP , KaragiannidisA , ChristidouA , KoilakouS , TsounisD , et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid‐dependent Crohn's disease. Gastroenterology2004;126:A54. ">Mantzaris 2004</a> was given an unclear risk of bias assessment as it was an abstract and did not describe all outcomes in the methods section and no protocol could be located. All of the other studies received a low risk of bias assessment for selective reporting. </p> </section> <section id="CD000067-sec-0048"> <h4 class="title">Other potential sources of bias</h4> <p>All studies were deemed to be at low risk of bias for other potential sources of bias, except <a href="./references#CD000067-bbs2-0002" title="CosnesJ , BourrierA , BouhnikY , LaharieD , NahonS , BonnetJ , et al. Accelerated step‐care therapy with early azathioprine (AZA) vs. conventional step‐care therapy in Crohn's disease: a randomized study. Gastroenterology2012;142(5 Suppl 1):S161. CosnesJ , BourrierA , LaharieD , NahonS , BouhnikY , CarbonnelF , et al. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology2013;145(4):758‐65.e2; quiz e14‐5. ">Cosnes 2013</a>, which received a unclear risk because this study included patients who had active disease and could change medications from the study medications to secondary study medications, but these changes were not described. </p> </section> </section> <section id="CD000067-sec-0049"> <h3 class="title" id="CD000067-sec-0049">Effects of interventions</h3> <p>See: <a href="./full#CD000067-tbl-0001"><b>Summary of findings for the main comparison</b> Azathioprine or 6‐mercaptopurine versus placebo for maintenance of remission in Crohn's disease</a>; <a href="./full#CD000067-tbl-0002"><b>Summary of findings 2</b> Azathioprine or 6‐mercaptopurine versus mesalazine or sulfasalazine for maintenance of remission in Crohn's disease</a>; <a href="./full#CD000067-tbl-0003"><b>Summary of findings 3</b> Azathioprine versus budesonide for maintenance of remission in Crohn's disease</a>; <a href="./full#CD000067-tbl-0004"><b>Summary of findings 4</b> Azathioprine and infliximab versus infliximab for maintenance of remission in Crohn's disease</a>; <a href="./full#CD000067-tbl-0005"><b>Summary of findings 5</b> 6‐Mercaptopurine versus methotrexate for maintenance of remission in Crohn's disease</a> </p> <section id="CD000067-sec-0050"> <h4 class="title">Maintenance of remission</h4> <p><b><i>Azathioprine versus placebo</i> </b> </p> <p>Azathioprine was compared to placebo in seven studies (<a href="./references#CD000067-bbs2-0001" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. CandyS , WrightJP , GerberM , AdamsG , GerigM , GoodmanR . A double blind controlled study of azathioprine in the treatment and maintenance of remission in Crohn's disease [abstract]. Gastroenterology1994;106:A659. ">Candy 1995</a>; <a href="./references#CD000067-bbs2-0003" title="ColombelJF , LemannM , BouhnikY , DuclosB , SouleJC , LereboursE , et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology2003;124(4 Suppl 1):A196‐7. LemannM , BouhnikY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. Randomized, double‐blind, placebo‐controlled, multicenter, azathioprine (AZA) withdrawal trial in Crohn’s disease (CD). Gastroenterology2002;122(4 Suppl 1):A23. LémannM , MaryJY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. A randomized, double‐blind, controlled withdrawal trial in Crohn's disease patients in long‐term remission on azathioprine. Gastroenterology2005;128(7):1812‐8. ">Lémann 2005</a>; <a href="./references#CD000067-bbs2-0007" title="O'DonoghueDP , DawsonAM , Powell‐TuckJ . Azathioprine as a maintenance treatment for Crohn's disease: a double blind withdrawal trial. Gastroenterology1978;72(5 II):1138. O'DonoghueDP , DawsonAM , Powell‐TuckJ , BownRL , Lennard‐JonesJE . Double‐blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet1978;2:955‐7. ">O'Donoghue 1978</a>; <a href="./references#CD000067-bbs2-0008" title="PanésJ , López‐SanrománA , BermejoF , García‐SánchezV , EsteveM , TorresY , et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology2013;145(4):766‐74. SansM , López‐San RomainA , EsteveM , BermejoF , Garcia‐SánchezV , TorresY , et al. Early use of azathioprine has a steroid sparing effect on recently diagnosed Crohn's disease patients. Gastroenterology2012;142(5 Suppl 1):S109. ">Panes 2013</a>; <a href="./references#CD000067-bbs2-0009" title="RosenbergJL , LevinB , WallAJ , KirsnerJB . A controlled trial of azathioprine in Crohn's disease. American Journal of Digestive Diseases1975;20:721‐6. ">Rosenberg 1975</a>; <a href="./references#CD000067-bbs2-0010" title="SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology1979;77:870‐82. SummersRW , SingletonJW . National Cooperative Crohn's Disease Study (NCCDS): a controlled prospective trial of three drugs vs placebo. Gut1977;18(11):A972‐3. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77:847‐69. ">Summers 1979</a>; <a href="./references#CD000067-bbs2-0011" title="WilloughbyJM , BeckettJ , KumarPJ , DawsonAM . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2:944‐7. WilloughbyJM , KumarP , BeckettJ , DawsonAM . A double‐blind trial of azathioprine in Crohn's disease. Gut1971;12(10):864. ">Willoughby 1971</a>). Two of the studies included an induction phase prior to the maintenance phase; as per protocol in the studies, only the patients entering remission in the induction phase were included in the maintenance phase (<a href="./references#CD000067-bbs2-0001" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. CandyS , WrightJP , GerberM , AdamsG , GerigM , GoodmanR . A double blind controlled study of azathioprine in the treatment and maintenance of remission in Crohn's disease [abstract]. Gastroenterology1994;106:A659. ">Candy 1995</a>; <a href="./references#CD000067-bbs2-0010" title="SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology1979;77:870‐82. SummersRW , SingletonJW . National Cooperative Crohn's Disease Study (NCCDS): a controlled prospective trial of three drugs vs placebo. Gut1977;18(11):A972‐3. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77:847‐69. ">Summers 1979</a> Part 1). The pooled analysis contains data from the maintenance phase of these two studies. The pooled analysis contains subgroups based on azathioprine doses used in the various studious; 2.5 mg/kg/day (<a href="./references#CD000067-bbs2-0001" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. CandyS , WrightJP , GerberM , AdamsG , GerigM , GoodmanR . A double blind controlled study of azathioprine in the treatment and maintenance of remission in Crohn's disease [abstract]. Gastroenterology1994;106:A659. ">Candy 1995</a>; <a href="./references#CD000067-bbs2-0008" title="PanésJ , López‐SanrománA , BermejoF , García‐SánchezV , EsteveM , TorresY , et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology2013;145(4):766‐74. SansM , López‐San RomainA , EsteveM , BermejoF , Garcia‐SánchezV , TorresY , et al. Early use of azathioprine has a steroid sparing effect on recently diagnosed Crohn's disease patients. Gastroenterology2012;142(5 Suppl 1):S109. ">Panes 2013</a>; <a href="./references#CD000067-bbs2-0010" title="SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology1979;77:870‐82. SummersRW , SingletonJW . National Cooperative Crohn's Disease Study (NCCDS): a controlled prospective trial of three drugs vs placebo. Gut1977;18(11):A972‐3. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77:847‐69. ">Summers 1979</a> Part 1), 2.0 mg/kg/day (<a href="./references#CD000067-bbs2-0003" title="ColombelJF , LemannM , BouhnikY , DuclosB , SouleJC , LereboursE , et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology2003;124(4 Suppl 1):A196‐7. LemannM , BouhnikY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. Randomized, double‐blind, placebo‐controlled, multicenter, azathioprine (AZA) withdrawal trial in Crohn’s disease (CD). Gastroenterology2002;122(4 Suppl 1):A23. LémannM , MaryJY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. A randomized, double‐blind, controlled withdrawal trial in Crohn's disease patients in long‐term remission on azathioprine. Gastroenterology2005;128(7):1812‐8. ">Lémann 2005</a>; <a href="./references#CD000067-bbs2-0007" title="O'DonoghueDP , DawsonAM , Powell‐TuckJ . Azathioprine as a maintenance treatment for Crohn's disease: a double blind withdrawal trial. Gastroenterology1978;72(5 II):1138. O'DonoghueDP , DawsonAM , Powell‐TuckJ , BownRL , Lennard‐JonesJE . Double‐blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet1978;2:955‐7. ">O'Donoghue 1978</a>; <a href="./references#CD000067-bbs2-0009" title="RosenbergJL , LevinB , WallAJ , KirsnerJB . A controlled trial of azathioprine in Crohn's disease. American Journal of Digestive Diseases1975;20:721‐6. ">Rosenberg 1975</a>; <a href="./references#CD000067-bbs2-0011" title="WilloughbyJM , BeckettJ , KumarPJ , DawsonAM . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2:944‐7. WilloughbyJM , KumarP , BeckettJ , DawsonAM . A double‐blind trial of azathioprine in Crohn's disease. Gut1971;12(10):864. ">Willoughby 1971</a>) and 1.0 mg/kg/day (<a href="./references#CD000067-bbs2-0010" title="SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology1979;77:870‐82. SummersRW , SingletonJW . National Cooperative Crohn's Disease Study (NCCDS): a controlled prospective trial of three drugs vs placebo. Gut1977;18(11):A972‐3. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77:847‐69. ">Summers 1979</a> Part 2). In total, 532 patients were included in the pooled analysis. There was a statistically significant difference in the proportion of patients who maintained remission over 6 to 18 months favouring azathioprine over placebo. Seventy‐two per cent (175/244) of azathioprine patients were in remission at study endpoint compared to 58% (168/288) of placebo patients (RR 1.25, 95% CI 1.11 to 1.42). These studies were moderately heterogeneous (I² = 38%). We visually inspected the forest plot and one study appeared to be an outlier (<a href="./references#CD000067-bbs2-0001" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. CandyS , WrightJP , GerberM , AdamsG , GerigM , GoodmanR . A double blind controlled study of azathioprine in the treatment and maintenance of remission in Crohn's disease [abstract]. Gastroenterology1994;106:A659. ">Candy 1995</a>). Further evaluation of the study characteristics showed that <a href="./references#CD000067-bbs2-0001" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. CandyS , WrightJP , GerberM , AdamsG , GerigM , GoodmanR . A double blind controlled study of azathioprine in the treatment and maintenance of remission in Crohn's disease [abstract]. Gastroenterology1994;106:A659. ">Candy 1995</a> used a CDAI of less than 175 as criteria for remission, which was different from all the other studies using CDAI. A sensitivity analysis excluding <a href="./references#CD000067-bbs2-0001" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. CandyS , WrightJP , GerberM , AdamsG , GerigM , GoodmanR . A double blind controlled study of azathioprine in the treatment and maintenance of remission in Crohn's disease [abstract]. Gastroenterology1994;106:A659. ">Candy 1995</a> appears to explain the heterogeneity. The pooled analysis included six studies and 489 participants and there was a statistically significant difference in the proportion of patients who maintained remission over 6 to 18 months favouring azathioprine over placebo. Seventy‐three per cent (161/220) of azathioprine remained in remission at study endpoint compared to 62% (166/269) of placebo patients (RR 1.19, 95% CI 1.05 to 1.34; I<sup>2</sup> = 0%). The number needed to treat for an additional beneficial outcome was 9. A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was low due to sparse data (327 events) and an unclear risk of bias in 5 of the studies in the pooled analysis. The pooled analysis for the 2.0 mg/kg/day subgroup showed a statistically significant difference favouring azathioprine over placebo (RR 1.33, 95% CI 1.10 to 1.61). There were no statistically significant differences between azathioprine and placebo for the 2.5 mg/kg/day (RR 1.17, 95% CI 0.94 to 1.45) or 1.0 mg/kg/day (RR 1.06, 95% CI 0.84 to 1.34) subgroups. </p> <p><b><i>Azathioprine or 6‐mercaptopurine versus mesalazine or sulfasalazine</i> </b> </p> <p><a href="./references#CD000067-bbs2-0006" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero PernoaJ , Moreno OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12:1227‐33. ">Maté‐Jiménez 2000</a> and <a href="./references#CD000067-bbs2-0010" title="SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology1979;77:870‐82. SummersRW , SingletonJW . National Cooperative Crohn's Disease Study (NCCDS): a controlled prospective trial of three drugs vs placebo. Gut1977;18(11):A972‐3. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77:847‐69. ">Summers 1979</a> (Part 1, phase 2 and Part 2) compared azathioprine or 6‐mercaptopurine to mesalazine or sulfasalazine. A pooled analysis of these studies included 166 patients. Subgroups are reported for the various doses of azathioprine and 6‐mercaptopurine: azathioprine 2 to 2.5 mg/kg/day, azathioprine 1.0 mg/kg/day and 6‐mercaptopurine 50 mg/day. There was no statistically significant difference in the proportion of patients who maintained remission at 12 months. Sixty‐nine percent (61/88) of participants maintained remission on azathioprine or 6‐mercaptopurine compared to 67% (52/78) who maintained remission on mesalamine or sulfasalazine (RR 1.09, 95% CI 0.88 to 1.34). The studies were not found to be heterogeneous (P = 0.72; I² = 0%). A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was low due to sparse data (113 events) and risk of bias. The risk of bias in the <a href="./references#CD000067-bbs2-0006" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero PernoaJ , Moreno OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12:1227‐33. ">Maté‐Jiménez 2000</a> study was high and the risk of bias in the <a href="./references#CD000067-bbs2-0010" title="SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology1979;77:870‐82. SummersRW , SingletonJW . National Cooperative Crohn's Disease Study (NCCDS): a controlled prospective trial of three drugs vs placebo. Gut1977;18(11):A972‐3. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77:847‐69. ">Summers 1979</a> study was unclear. </p> <p><b><i>Azathioprine versus budesonide</i> </b> </p> <p>Azathioprine was compared to budesonide in one small study (<a href="./references#CD000067-bbs2-0005" title="MantzarisG , ChristidouA , SfakianakisM , RoussosA , KoilakouS , PetrakiK , et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn's disease. Inflammtory Bowel Diseases2009;15:375‐82. MantzarisGJ , PetrakiK , Chadio‐IordanidesH , ChristidouA , KaragiannidisA , GlarakisJ , et al. Maintenance therapy with azathioprine is superior to budesonide in healing endoscopic lesions and improving histology in clinically quiescent Crohn's disease. Gastroenterology2002;122(4 Suppl 1):A81. ">Mantzaris 2009</a>). There was a statistically significant difference in the proportion of patients who maintained remission at 12 months favouring azathioprine over budesonide. Seventy‐six per cent (29/38) of patients in the azathioprine group maintained remission compared to 46% (18/39) of budesonide patients (RR 1.65, 95% CI 1.13 to 2.42). A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was low due to sparse data (47 events) and high risk of bias. </p> <p><b><i>Azathioprine + infliximab versus infliximab</i> </b> </p> <p>One small study compared combination therapy with infliximab and azathioprine to infliximab monotherapy. There was no statistically significant difference in the proportion of patients who maintained remission at 12 months. Eighty‐one per cent (13/16) of patients in the combination therapy group maintained remission compared to 80% (16/20) of patients in the infliximab monotherapy group (RR 1.02, 95% CI 0.74 to 1.40). A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was very low due to very sparse data (29 events) and high risk of bias. </p> <p><b><i>6‐Mercaptopurine versus methotrexate</i> </b> </p> <p><a href="./references#CD000067-bbs2-0006" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero PernoaJ , Moreno OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12:1227‐33. ">Maté‐Jiménez 2000</a> compared 6‐mercaptopurine to methotrexate. There was no statistically significant difference in the proportion of patients who maintained remission at 76 weeks. Fifty per cent (8/16) of patients in the 6‐mercaptopurine group maintained remission at 76 weeks compared to 53% (8/15) of methotrexate patients (RR 0.94, 95% CI 0.47 to 1.85). A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was very low due to very sparse data (16 events) and high risk of bias. </p> <p><b>Early administration of azathioprine versus conventional management</b> </p> <p>One study (N = 147 participants) compared the early administration of azathioprine to a conventional management strategy (<a href="./references#CD000067-bbs2-0002" title="CosnesJ , BourrierA , BouhnikY , LaharieD , NahonS , BonnetJ , et al. Accelerated step‐care therapy with early azathioprine (AZA) vs. conventional step‐care therapy in Crohn's disease: a randomized study. Gastroenterology2012;142(5 Suppl 1):S161. CosnesJ , BourrierA , LaharieD , NahonS , BouhnikY , CarbonnelF , et al. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology2013;145(4):758‐65.e2; quiz e14‐5. ">Cosnes 2013</a>). The study failed to show any significant benefit for early azathioprine treatment over a conventional management strategy. In the early azathioprine treatment group 67% (11‐85%) of trimesters were spent in remission compared to 56% (29‐73%) in the conventional management group. </p> </section> <section id="CD000067-sec-0051"> <h4 class="title">Adverse events</h4> <p><b><i>Azathioprine or 6‐mercaptopurine versus placebo</i> </b> </p> <p>Safety data were reported in each of the seven studies that compared azathioprine to placebo. Three of the seven studies include data for adverse events, withdrawals due to adverse events and serious adverse events (<a href="./references#CD000067-bbs2-0003" title="ColombelJF , LemannM , BouhnikY , DuclosB , SouleJC , LereboursE , et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology2003;124(4 Suppl 1):A196‐7. LemannM , BouhnikY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. Randomized, double‐blind, placebo‐controlled, multicenter, azathioprine (AZA) withdrawal trial in Crohn’s disease (CD). Gastroenterology2002;122(4 Suppl 1):A23. LémannM , MaryJY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. A randomized, double‐blind, controlled withdrawal trial in Crohn's disease patients in long‐term remission on azathioprine. Gastroenterology2005;128(7):1812‐8. ">Lémann 2005</a>; <a href="./references#CD000067-bbs2-0007" title="O'DonoghueDP , DawsonAM , Powell‐TuckJ . Azathioprine as a maintenance treatment for Crohn's disease: a double blind withdrawal trial. Gastroenterology1978;72(5 II):1138. O'DonoghueDP , DawsonAM , Powell‐TuckJ , BownRL , Lennard‐JonesJE . Double‐blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet1978;2:955‐7. ">O'Donoghue 1978</a>; <a href="./references#CD000067-bbs2-0008" title="PanésJ , López‐SanrománA , BermejoF , García‐SánchezV , EsteveM , TorresY , et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology2013;145(4):766‐74. SansM , López‐San RomainA , EsteveM , BermejoF , Garcia‐SánchezV , TorresY , et al. Early use of azathioprine has a steroid sparing effect on recently diagnosed Crohn's disease patients. Gastroenterology2012;142(5 Suppl 1):S109. ">Panes 2013</a>). <a href="./references#CD000067-bbs2-0010" title="SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology1979;77:870‐82. SummersRW , SingletonJW . National Cooperative Crohn's Disease Study (NCCDS): a controlled prospective trial of three drugs vs placebo. Gut1977;18(11):A972‐3. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77:847‐69. ">Summers 1979</a> didn't report on the proportion of patients who experienced at least one adverse event. Three studies did not report on serious adverse events (<a href="./references#CD000067-bbs2-0001" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. CandyS , WrightJP , GerberM , AdamsG , GerigM , GoodmanR . A double blind controlled study of azathioprine in the treatment and maintenance of remission in Crohn's disease [abstract]. Gastroenterology1994;106:A659. ">Candy 1995</a>; <a href="./references#CD000067-bbs2-0009" title="RosenbergJL , LevinB , WallAJ , KirsnerJB . A controlled trial of azathioprine in Crohn's disease. American Journal of Digestive Diseases1975;20:721‐6. ">Rosenberg 1975</a>; <a href="./references#CD000067-bbs2-0011" title="WilloughbyJM , BeckettJ , KumarPJ , DawsonAM . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2:944‐7. WilloughbyJM , KumarP , BeckettJ , DawsonAM . A double‐blind trial of azathioprine in Crohn's disease. Gut1971;12(10):864. ">Willoughby 1971</a>). The studies including an induction phase (<a href="./references#CD000067-bbs2-0001" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. CandyS , WrightJP , GerberM , AdamsG , GerigM , GoodmanR . A double blind controlled study of azathioprine in the treatment and maintenance of remission in Crohn's disease [abstract]. Gastroenterology1994;106:A659. ">Candy 1995</a>; <a href="./references#CD000067-bbs2-0010" title="SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology1979;77:870‐82. SummersRW , SingletonJW . National Cooperative Crohn's Disease Study (NCCDS): a controlled prospective trial of three drugs vs placebo. Gut1977;18(11):A972‐3. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77:847‐69. ">Summers 1979</a>), did not describe safety data by trial phase and it is unknown whether the adverse events occurred during the induction or maintenance phase. Similarly, <a href="./references#CD000067-bbs2-0011" title="WilloughbyJM , BeckettJ , KumarPJ , DawsonAM . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2:944‐7. WilloughbyJM , KumarP , BeckettJ , DawsonAM . A double‐blind trial of azathioprine in Crohn's disease. Gut1971;12(10):864. ">Willoughby 1971</a>, did not separate the reported toxicity data by group, and instead reported it across all study participants. For these studies we report the safety data that were available. </p> <p>A pooled analysis of six studies (359 participants) showed that a significantly higher proportion of azathioprine patients experienced at least one adverse event compared to placebo (<a href="./references#CD000067-bbs2-0001" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. CandyS , WrightJP , GerberM , AdamsG , GerigM , GoodmanR . A double blind controlled study of azathioprine in the treatment and maintenance of remission in Crohn's disease [abstract]. Gastroenterology1994;106:A659. ">Candy 1995</a>; <a href="./references#CD000067-bbs2-0003" title="ColombelJF , LemannM , BouhnikY , DuclosB , SouleJC , LereboursE , et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology2003;124(4 Suppl 1):A196‐7. LemannM , BouhnikY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. Randomized, double‐blind, placebo‐controlled, multicenter, azathioprine (AZA) withdrawal trial in Crohn’s disease (CD). Gastroenterology2002;122(4 Suppl 1):A23. LémannM , MaryJY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. A randomized, double‐blind, controlled withdrawal trial in Crohn's disease patients in long‐term remission on azathioprine. Gastroenterology2005;128(7):1812‐8. ">Lémann 2005</a>; <a href="./references#CD000067-bbs2-0007" title="O'DonoghueDP , DawsonAM , Powell‐TuckJ . Azathioprine as a maintenance treatment for Crohn's disease: a double blind withdrawal trial. Gastroenterology1978;72(5 II):1138. O'DonoghueDP , DawsonAM , Powell‐TuckJ , BownRL , Lennard‐JonesJE . Double‐blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet1978;2:955‐7. ">O'Donoghue 1978</a>; <a href="./references#CD000067-bbs2-0008" title="PanésJ , López‐SanrománA , BermejoF , García‐SánchezV , EsteveM , TorresY , et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology2013;145(4):766‐74. SansM , López‐San RomainA , EsteveM , BermejoF , Garcia‐SánchezV , TorresY , et al. Early use of azathioprine has a steroid sparing effect on recently diagnosed Crohn's disease patients. Gastroenterology2012;142(5 Suppl 1):S109. ">Panes 2013</a>; <a href="./references#CD000067-bbs2-0009" title="RosenbergJL , LevinB , WallAJ , KirsnerJB . A controlled trial of azathioprine in Crohn's disease. American Journal of Digestive Diseases1975;20:721‐6. ">Rosenberg 1975</a>; <a href="./references#CD000067-bbs2-0011" title="WilloughbyJM , BeckettJ , KumarPJ , DawsonAM . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2:944‐7. WilloughbyJM , KumarP , BeckettJ , DawsonAM . A double‐blind trial of azathioprine in Crohn's disease. Gut1971;12(10):864. ">Willoughby 1971</a>). Thirty‐three per cent of azathioprine patients experienced at least one adverse event compared to 25% of placebo patients (RR 1.29, 95% CI 1.02 to 1.64). A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was low due to sparse data (104 events) and unclear risk of bias. Five of the studies in the pooled analysis were rated as unclear risk of bias for random sequence generation, allocation concealment or incomplete outcome data. </p> <p>A pooled analysis of seven studies (661 participants) showed that a significantly higher proportion of azathioprine patients withdrew due to adverse events compared to placebo (<a href="./references#CD000067-bbs2-0001" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. CandyS , WrightJP , GerberM , AdamsG , GerigM , GoodmanR . A double blind controlled study of azathioprine in the treatment and maintenance of remission in Crohn's disease [abstract]. Gastroenterology1994;106:A659. ">Candy 1995</a>; <a href="./references#CD000067-bbs2-0003" title="ColombelJF , LemannM , BouhnikY , DuclosB , SouleJC , LereboursE , et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology2003;124(4 Suppl 1):A196‐7. LemannM , BouhnikY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. Randomized, double‐blind, placebo‐controlled, multicenter, azathioprine (AZA) withdrawal trial in Crohn’s disease (CD). Gastroenterology2002;122(4 Suppl 1):A23. LémannM , MaryJY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. A randomized, double‐blind, controlled withdrawal trial in Crohn's disease patients in long‐term remission on azathioprine. Gastroenterology2005;128(7):1812‐8. ">Lémann 2005</a>; <a href="./references#CD000067-bbs2-0007" title="O'DonoghueDP , DawsonAM , Powell‐TuckJ . Azathioprine as a maintenance treatment for Crohn's disease: a double blind withdrawal trial. Gastroenterology1978;72(5 II):1138. O'DonoghueDP , DawsonAM , Powell‐TuckJ , BownRL , Lennard‐JonesJE . Double‐blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet1978;2:955‐7. ">O'Donoghue 1978</a>; <a href="./references#CD000067-bbs2-0008" title="PanésJ , López‐SanrománA , BermejoF , García‐SánchezV , EsteveM , TorresY , et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology2013;145(4):766‐74. SansM , López‐San RomainA , EsteveM , BermejoF , Garcia‐SánchezV , TorresY , et al. Early use of azathioprine has a steroid sparing effect on recently diagnosed Crohn's disease patients. Gastroenterology2012;142(5 Suppl 1):S109. ">Panes 2013</a>; <a href="./references#CD000067-bbs2-0009" title="RosenbergJL , LevinB , WallAJ , KirsnerJB . A controlled trial of azathioprine in Crohn's disease. American Journal of Digestive Diseases1975;20:721‐6. ">Rosenberg 1975</a>; <a href="./references#CD000067-bbs2-0010" title="SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology1979;77:870‐82. SummersRW , SingletonJW . National Cooperative Crohn's Disease Study (NCCDS): a controlled prospective trial of three drugs vs placebo. Gut1977;18(11):A972‐3. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77:847‐69. ">Summers 1979</a>; <a href="./references#CD000067-bbs2-0011" title="WilloughbyJM , BeckettJ , KumarPJ , DawsonAM . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2:944‐7. WilloughbyJM , KumarP , BeckettJ , DawsonAM . A double‐blind trial of azathioprine in Crohn's disease. Gut1971;12(10):864. ">Willoughby 1971</a>). Nine per cent (28/299) of azathioprine patients withdrew due to adverse events compared to 2% (9/362) of placebo patients (RR 3.12, 95% CI 1.59 to 6.09). A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was very low due to very sparse data (37 events) and unclear risk of bias. Five of the studies in the pooled analysis were rated as unclear risk of bias for random sequence generation, allocation concealment or incomplete outcome data. Common adverse events leading to withdrawal included pancreatitis, leukopenia, nausea, allergic reaction and infection. In a few patients, the adverse event causing withdrawal was not specified. </p> <p>A pooled analysis of four studies (556 patients) showed that a significantly higher proportion of azathioprine patients experienced a serious adverse event compared to placebo (<a href="./references#CD000067-bbs2-0003" title="ColombelJF , LemannM , BouhnikY , DuclosB , SouleJC , LereboursE , et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology2003;124(4 Suppl 1):A196‐7. LemannM , BouhnikY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. Randomized, double‐blind, placebo‐controlled, multicenter, azathioprine (AZA) withdrawal trial in Crohn’s disease (CD). Gastroenterology2002;122(4 Suppl 1):A23. LémannM , MaryJY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. A randomized, double‐blind, controlled withdrawal trial in Crohn's disease patients in long‐term remission on azathioprine. Gastroenterology2005;128(7):1812‐8. ">Lémann 2005</a>; <a href="./references#CD000067-bbs2-0007" title="O'DonoghueDP , DawsonAM , Powell‐TuckJ . Azathioprine as a maintenance treatment for Crohn's disease: a double blind withdrawal trial. Gastroenterology1978;72(5 II):1138. O'DonoghueDP , DawsonAM , Powell‐TuckJ , BownRL , Lennard‐JonesJE . Double‐blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet1978;2:955‐7. ">O'Donoghue 1978</a>; <a href="./references#CD000067-bbs2-0008" title="PanésJ , López‐SanrománA , BermejoF , García‐SánchezV , EsteveM , TorresY , et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology2013;145(4):766‐74. SansM , López‐San RomainA , EsteveM , BermejoF , Garcia‐SánchezV , TorresY , et al. Early use of azathioprine has a steroid sparing effect on recently diagnosed Crohn's disease patients. Gastroenterology2012;142(5 Suppl 1):S109. ">Panes 2013</a>; <a href="./references#CD000067-bbs2-0010" title="SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology1979;77:870‐82. SummersRW , SingletonJW . National Cooperative Crohn's Disease Study (NCCDS): a controlled prospective trial of three drugs vs placebo. Gut1977;18(11):A972‐3. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77:847‐69. ">Summers 1979</a>). Nine per cent (22/245) of azathioprine patients experienced a serious adverse event compared to 3% (9/311) of placebo patients (RR 2.45, 95% CI 1.22 to 4.90). A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was very low due to very sparse data (31 events) and unclear risk of bias.Two of the studies in the pooled analysis were rated as unclear risk of bias for random sequence generation, allocation concealment, blinding or incomplete outcome data. The most common serious adverse event was leukopenia. </p> <p><b><i>Azathioprine or 6‐mercaptopurine versus mesalazine or sulfasalazine</i> </b> </p> <p><a href="./references#CD000067-bbs2-0006" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero PernoaJ , Moreno OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12:1227‐33. ">Maté‐Jiménez 2000</a> found no statistically significant difference in the proportion of patients who experienced at least one adverse event. Twenty‐seven per cent (8/30) of 6‐mercaptopurine patients experienced at least one adverse event compared to 0% (0/15) of mesalazine patients (RR 8.77, 95% CI 0.54 to 142.51). A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was very low due to very sparse data (8 events) and high risk of bias. The most common adverse events experienced in the 6‐mercaptopurine group were leukopenia, nausea and diarrhoea, melanosis and mild alopecia, with leukopenia being a serious event. </p> <p>A pooled analysis of two studies (290 participants) showed no statistically significant difference in withdrawals due to adverse events (<a href="./references#CD000067-bbs2-0006" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero PernoaJ , Moreno OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12:1227‐33. ">Maté‐Jiménez 2000</a>; <a href="./references#CD000067-bbs2-0010" title="SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology1979;77:870‐82. SummersRW , SingletonJW . National Cooperative Crohn's Disease Study (NCCDS): a controlled prospective trial of three drugs vs placebo. Gut1977;18(11):A972‐3. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77:847‐69. ">Summers 1979</a>). Thirteen per cent (18/143) of patients in the azathioprine/6‐mercaptopurine group withdrew due to an adverse event compared to 7% (10/147) of patients in the mesalazine/sulfasalazine group (RR 1.86, 95% CI 0.87 to 3.97). A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was very low due to very sparse data (28 events) and unclear or high risk of bias. One study was rated as unclear risk of bias for random sequence generation and incomplete outcome data and the other study was rated as high risk of bias for no blinding. </p> <p>A pooled analysis of two studies (235 participants) showed a statistically significant difference in the proportion of patients who experienced a serious adverse event (<a href="./references#CD000067-bbs2-0006" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero PernoaJ , Moreno OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12:1227‐33. ">Maté‐Jiménez 2000</a>; <a href="./references#CD000067-bbs2-0010" title="SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology1979;77:870‐82. SummersRW , SingletonJW . National Cooperative Crohn's Disease Study (NCCDS): a controlled prospective trial of three drugs vs placebo. Gut1977;18(11):A972‐3. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77:847‐69. ">Summers 1979</a>). Thirteen per cent (16/125) of patients in the azathioprine/6‐mercaptopurine group had a serious adverse event compared to 0% (0/110) of patients in the mesalazine/sulfasalazine group (RR 9.37, 95% CI 1.84 to 47.72). A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was very low due to very sparse data (16 events) and unclear or high risk of bias. One study was rated as unclear risk of bias for random sequence generation and incomplete outcome data and the other study was rated as high risk of bias for no blinding. </p> <p><b><i>Azathioprine versus budesonide</i> </b> </p> <p><a href="./references#CD000067-bbs2-0005" title="MantzarisG , ChristidouA , SfakianakisM , RoussosA , KoilakouS , PetrakiK , et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn's disease. Inflammtory Bowel Diseases2009;15:375‐82. MantzarisGJ , PetrakiK , Chadio‐IordanidesH , ChristidouA , KaragiannidisA , GlarakisJ , et al. Maintenance therapy with azathioprine is superior to budesonide in healing endoscopic lesions and improving histology in clinically quiescent Crohn's disease. Gastroenterology2002;122(4 Suppl 1):A81. ">Mantzaris 2009</a> reported that 112 adverse events occurred in the 38 patients receiving azathioprine compared to 83 adverse events among the 39 patients in the budesonide group. The proportion of patients in each group who experienced at least one adverse event was not reported. Adverse events included pancreatitis, severe leukopenia, infections, transient abdominal pain, and diarrhea. Adverse events thought to be drug‐related included transient paresthesias, hair loss, and elevated transaminases in the azathioprine group and mild acne, moon face, and transient hair loss in the budesonide group. There was no statistically significant difference in the proportion of patients who withdrew due to adverse events. Five per cent (2/38) of azathioprine patients withdrew due to adverse events compared to 0% (0/39) of budesonide patients (RR 5.13, 95% CI 0.25 to 103.43). A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was very low due to very sparse data (2 events) and high risk of bias. The reported withdrawals were due to serious adverse events including pancreatitis and severe leukopenia. There was no statistically significant difference in the proportion of patients who experienced a serious adverse event (RR 5.13, 95% CI 0.25 to 103.43). A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was very low due to very sparse data (2 events) and high risk of bias. </p> <p><b><i>Azathioprine + infliximab versus infliximab</i> </b> </p> <p><a href="./references#CD000067-bbs2-0004" title="MantzarisGJ , PloyzouP , KaragiannidisA , ChristidouA , KoilakouS , TsounisD , et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid‐dependent Crohn's disease. Gastroenterology2004;126:A54. ">Mantzaris 2004</a> reported that there was no statistically significant difference in the proportion of patients who experienced at least one adverse event. Sixteen per cent (4/25) of patients in the combination therapy group experienced at least one adverse event compared to 10% (2/20) of patients in the infliximab monotherapy group (RR 1.60, 95% CI 0.33 to 7.86). A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was very low due to very sparse data (6 events) and unclear risk of bias. In the combination therapy group four patients had leukopenia, which was serious in one patient. In the infliximab monotherapy group two patients had acute infusion reactions. The only withdrawal due to an adverse event occurred in the combination therapy group (severe leukopenia also classified as a serious adverse event). There was no statistically significant difference in the proportion of patients who withdrew due to an adverse event or who experienced a serious adverse event (RR 2.42, 95% CI 0.10 to 56.46). GRADE analyses indicated that the overall quality of the evidence supporting these outcomes was very low due to very sparse data (1 event for both comparisons) and unclear risk of bias. </p> <p><b><i>6‐Mercaptopurine versus methotrexate</i> </b> </p> <p><a href="./references#CD000067-bbs2-0006" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero PernoaJ , Moreno OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12:1227‐33. ">Maté‐Jiménez 2000</a> reported no statistically significant differences in the proportion of patients who experienced at least one adverse event. Twenty‐seven per cent (8/30) of 6‐mercaptopurine patients experienced at least one adverse event compared to 41% (11/27) of methotrexate patients (RR 0.65, 95% CI 0.31 to 1.38). A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was very low due to very sparse data (19 events) and high risk of bias. Adverse events reported in the 6‐mercaptopurine group included leukopenia, nausea and diarrhoea, melanosis and mild alopecia, with leukopenia being a serious adverse event. Adverse events reported in the methotrexate group included nausea and vomiting, mild alopecia, increases in AST, development of perianal abscess, and serious adverse events including hypoalbuminemia, severe rash and atypical pneumonia. Withdrawals from the study were a result of serious adverse events in both arms of the trial. Ten per cent (3/30) of 6‐mercaptopurine patients (3/30) withdrew after a serious adverse event compared to 15% (4/27) of methotrexate patients. There was no statistically significant difference in the proportion of patients who withdrew due to an adverse event or who experienced a serious adverse event (RR 0.68, 95% CI 0.17 to 2.75). GRADE analyses indicated that the overall quality of the evidence supporting these outcomes was very low due to very sparse data (7 events for both comparisons) and high risk of bias. </p> </section> <section id="CD000067-sec-0052"> <h4 class="title">Steroid sparing</h4> <p>In the two very small studies reporting steroid sparing data (<a href="./references#CD000067-bbs2-0011" title="WilloughbyJM , BeckettJ , KumarPJ , DawsonAM . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2:944‐7. WilloughbyJM , KumarP , BeckettJ , DawsonAM . A double‐blind trial of azathioprine in Crohn's disease. Gut1971;12(10):864. ">Willoughby 1971</a>; <a href="./references#CD000067-bbs2-0009" title="RosenbergJL , LevinB , WallAJ , KirsnerJB . A controlled trial of azathioprine in Crohn's disease. American Journal of Digestive Diseases1975;20:721‐6. ">Rosenberg 1975</a>), 87% (13/15) patients receiving maintenance therapy with azathioprine were able to reduce or discontinue steroids (steroid sparing) compared to 53% (8/15) patients receiving placebo (RR 1.59, 95% CI 0.97 to 2.61). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD000067-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000067-sec-0053">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000067-sec-0090">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD000067-sec-0053"></div> <p>This systematic review included 11 randomized controlled trials (881 participants) that evaluated the efficacy and safety of azathioprine or 6‐mercaptopurine for maintaining remission achieved by medical therapy in patients with quiescent Crohn's disease. Seven studies compared azathioprine to placebo (<a href="./references#CD000067-bbs2-0001" title="CandyS , WrightJ , GerberM , AdamsG , GerigM , GoodmanR . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut1995;37(5):674‐8. CandyS , WrightJP , GerberM , AdamsG , GerigM , GoodmanR . A double blind controlled study of azathioprine in the treatment and maintenance of remission in Crohn's disease [abstract]. Gastroenterology1994;106:A659. ">Candy 1995</a>; <a href="./references#CD000067-bbs2-0003" title="ColombelJF , LemannM , BouhnikY , DuclosB , SouleJC , LereboursE , et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology2003;124(4 Suppl 1):A196‐7. LemannM , BouhnikY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. Randomized, double‐blind, placebo‐controlled, multicenter, azathioprine (AZA) withdrawal trial in Crohn’s disease (CD). Gastroenterology2002;122(4 Suppl 1):A23. LémannM , MaryJY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. A randomized, double‐blind, controlled withdrawal trial in Crohn's disease patients in long‐term remission on azathioprine. Gastroenterology2005;128(7):1812‐8. ">Lémann 2005</a>; <a href="./references#CD000067-bbs2-0007" title="O'DonoghueDP , DawsonAM , Powell‐TuckJ . Azathioprine as a maintenance treatment for Crohn's disease: a double blind withdrawal trial. Gastroenterology1978;72(5 II):1138. O'DonoghueDP , DawsonAM , Powell‐TuckJ , BownRL , Lennard‐JonesJE . Double‐blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet1978;2:955‐7. ">O'Donoghue 1978</a>; <a href="./references#CD000067-bbs2-0008" title="PanésJ , López‐SanrománA , BermejoF , García‐SánchezV , EsteveM , TorresY , et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology2013;145(4):766‐74. SansM , López‐San RomainA , EsteveM , BermejoF , Garcia‐SánchezV , TorresY , et al. Early use of azathioprine has a steroid sparing effect on recently diagnosed Crohn's disease patients. Gastroenterology2012;142(5 Suppl 1):S109. ">Panes 2013</a>; <a href="./references#CD000067-bbs2-0009" title="RosenbergJL , LevinB , WallAJ , KirsnerJB . A controlled trial of azathioprine in Crohn's disease. American Journal of Digestive Diseases1975;20:721‐6. ">Rosenberg 1975</a>; <a href="./references#CD000067-bbs2-0010" title="SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology1979;77:870‐82. SummersRW , SingletonJW . National Cooperative Crohn's Disease Study (NCCDS): a controlled prospective trial of three drugs vs placebo. Gut1977;18(11):A972‐3. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77:847‐69. ">Summers 1979</a>; <a href="./references#CD000067-bbs2-0011" title="WilloughbyJM , BeckettJ , KumarPJ , DawsonAM . Controlled trial of azathioprine in Crohn's disease. Lancet1971;2:944‐7. WilloughbyJM , KumarP , BeckettJ , DawsonAM . A double‐blind trial of azathioprine in Crohn's disease. Gut1971;12(10):864. ">Willoughby 1971</a>). <a href="./references#CD000067-bbs2-0010" title="SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology1979;77:870‐82. SummersRW , SingletonJW . National Cooperative Crohn's Disease Study (NCCDS): a controlled prospective trial of three drugs vs placebo. Gut1977;18(11):A972‐3. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77:847‐69. ">Summers 1979</a> also compared azathioprine to sulfasalazine. <a href="./references#CD000067-bbs2-0006" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero PernoaJ , Moreno OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12:1227‐33. ">Maté‐Jiménez 2000</a> compared 6‐mercaptopurine to mesalazine or methotrexate. One study compared azathioprine to budesonide (<a href="./references#CD000067-bbs2-0005" title="MantzarisG , ChristidouA , SfakianakisM , RoussosA , KoilakouS , PetrakiK , et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn's disease. Inflammtory Bowel Diseases2009;15:375‐82. MantzarisGJ , PetrakiK , Chadio‐IordanidesH , ChristidouA , KaragiannidisA , GlarakisJ , et al. Maintenance therapy with azathioprine is superior to budesonide in healing endoscopic lesions and improving histology in clinically quiescent Crohn's disease. Gastroenterology2002;122(4 Suppl 1):A81. ">Mantzaris 2009</a>); one study compared the combination of azathioprine and infliximab to infliximab monotherapy (<a href="./references#CD000067-bbs2-0004" title="MantzarisGJ , PloyzouP , KaragiannidisA , ChristidouA , KoilakouS , TsounisD , et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid‐dependent Crohn's disease. Gastroenterology2004;126:A54. ">Mantzaris 2004</a>); and one study compared 6‐mercaptopurine to methotrexate (<a href="./references#CD000067-bbs2-0006" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero PernoaJ , Moreno OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12:1227‐33. ">Maté‐Jiménez 2000</a>). One study compared the early administration of azathioprine to a conventional management strategy (<a href="./references#CD000067-bbs2-0002" title="CosnesJ , BourrierA , BouhnikY , LaharieD , NahonS , BonnetJ , et al. Accelerated step‐care therapy with early azathioprine (AZA) vs. conventional step‐care therapy in Crohn's disease: a randomized study. Gastroenterology2012;142(5 Suppl 1):S161. CosnesJ , BourrierA , LaharieD , NahonS , BouhnikY , CarbonnelF , et al. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology2013;145(4):758‐65.e2; quiz e14‐5. ">Cosnes 2013</a>). </p> <p>A pooled analysis of six studies (489 participants) suggests that azathioprine (1.0 to 2.5 mg/kg/day) is superior to placebo for maintenance of remission in quiescent Crohn's disease over a 6 to 18 month period. The number needed to treat for an additional beneficial outcome was nine. A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was low due to sparse data (327 events) and unclear risk of bias. Five of the studies in the pooled analysis were rated as unclear risk of bias for random sequence generation, allocation concealment or incomplete outcome data. Although azathioprine may be effective for maintenance of remission it is associated with a significantly increased risk of adverse events, withdrawal due to adverse events and serious adverse events relative to placebo. Common adverse events reported in the placebo‐controlled trials include pancreatitis, leukopenia, nausea, allergic reaction and infection. The adverse effects of azathioprine are well recognized in clinical practice and limit its use. Azathioprine‐related serious adverse events lead to cessation of therapy in 9 to 25% of patients (<a href="./references#CD000067-bbs2-0044" title="GearryRB , BarclayML , BurtMJ , CollettJA , ChapmanBA . Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiology and Drug Safety2004;13(8):563‐7. ">Gearry 2004</a>; <a href="./references#CD000067-bbs2-0045" title="GearryRB , BarclayML . Azathioprine and 6‐mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. Journal of Gastroenterology and Hepatology2005;20(8):1149‐57. ">Gearry 2005</a>). Adverse events associated with azathioprine and 6‐mercaptopurine include nausea, allergic reaction, flu‐like illness, malaise, fevers, rash, abdominal pain, pancreatitis, hepatotoxicity, myelosuppression, and an increased risk of lymphoma (<a href="./references#CD000067-bbs2-0042" title="DubinskyMC . Azathioprine, 6‐mercaptopurine in inflammatory bowel disease: Pharmacology, efficacy, and safety. Clinical Gastroenterology and Hepatology2004;2(9):731‐43. ">Dubinsky 2004</a>; <a href="./references#CD000067-bbs2-0051" title="KandielA , FraserAG , KorelitzBI , BrensingerC , LewisJD . Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6‐mercaptopurine. Gut2005;54(8):1121‐5. ">Kandiel 2005</a>; <a href="./references#CD000067-bbs2-0039" title="BeaugerieL , CarratF , BouvierAM , BrousseN , CarbonnelF , ColombelJF , et al. Excess risk of lymphoproliferative disorders (Lpd) in inflammatory bowel diseases (IBD): Interim results of the Cesame cohort. Gastroenterology2008;134(4 Suppl 1):A116. ">Beaugerie 2008</a>). Advances in the understanding of azathioprine and 6‐mercaptopurine drug metabolism have led to genetic and metabolite tests to help clinicians optimise the use of these drugs. Thiopurine methyltransferase (TPMT) enzyme activity can predict potentially life threatening myelosuppression in patients who are TPMT‐deficient (<a href="./references#CD000067-bbs2-0042" title="DubinskyMC . Azathioprine, 6‐mercaptopurine in inflammatory bowel disease: Pharmacology, efficacy, and safety. Clinical Gastroenterology and Hepatology2004;2(9):731‐43. ">Dubinsky 2004</a>; <a href="./references#CD000067-bbs2-0045" title="GearryRB , BarclayML . Azathioprine and 6‐mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. Journal of Gastroenterology and Hepatology2005;20(8):1149‐57. ">Gearry 2005</a>). TPMT may also aid in determining optimal dosing (<a href="./references#CD000067-bbs2-0042" title="DubinskyMC . Azathioprine, 6‐mercaptopurine in inflammatory bowel disease: Pharmacology, efficacy, and safety. Clinical Gastroenterology and Hepatology2004;2(9):731‐43. ">Dubinsky 2004</a>; <a href="./references#CD000067-bbs2-0045" title="GearryRB , BarclayML . Azathioprine and 6‐mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. Journal of Gastroenterology and Hepatology2005;20(8):1149‐57. ">Gearry 2005</a>). 6‐Thioguanine nucleotides and 6‐methylmercaptopurine concentrations are helpful in determining why a patient does not respond to a standard dose of azathioprine or 6‐mercaptopurine and may help avoid myelosuppression (<a href="./references#CD000067-bbs2-0042" title="DubinskyMC . Azathioprine, 6‐mercaptopurine in inflammatory bowel disease: Pharmacology, efficacy, and safety. Clinical Gastroenterology and Hepatology2004;2(9):731‐43. ">Dubinsky 2004</a>; <a href="./references#CD000067-bbs2-0045" title="GearryRB , BarclayML . Azathioprine and 6‐mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. Journal of Gastroenterology and Hepatology2005;20(8):1149‐57. ">Gearry 2005</a>). The ratio of these metabolites can help differentiate between non‐compliance, under‐dosing, and drug resistance or refractory states (<a href="./references#CD000067-bbs2-0042" title="DubinskyMC . Azathioprine, 6‐mercaptopurine in inflammatory bowel disease: Pharmacology, efficacy, and safety. Clinical Gastroenterology and Hepatology2004;2(9):731‐43. ">Dubinsky 2004</a>; <a href="./references#CD000067-bbs2-0045" title="GearryRB , BarclayML . Azathioprine and 6‐mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. Journal of Gastroenterology and Hepatology2005;20(8):1149‐57. ">Gearry 2005</a>). More research is required to determine the optimal use of these tests in patients with Crohn's disease. However, a randomized controlled trial looking at the role of metabolite monitoring proved not to be feasible and was terminated due to slow patient recruitment (<a href="./references#CD000067-bbs2-0052" title="National Institute of Diabetes and Digestive and Kidney Diseases. A multi‐site trial of azathioprine dosing in Crohn's disease. ClinicalTrials.gov, NCT00113503,2008. [NCT00113503] ">NIDDK 2008</a>). </p> <p>The results of one small study (77 participants) suggest that azathioprine (2.0 to 2.5 mg/kg/day) may be superior to budesonide (6 to 9 mg/day) for maintenance of remission at one year (<a href="./references#CD000067-bbs2-0005" title="MantzarisG , ChristidouA , SfakianakisM , RoussosA , KoilakouS , PetrakiK , et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn's disease. Inflammtory Bowel Diseases2009;15:375‐82. MantzarisGJ , PetrakiK , Chadio‐IordanidesH , ChristidouA , KaragiannidisA , GlarakisJ , et al. Maintenance therapy with azathioprine is superior to budesonide in healing endoscopic lesions and improving histology in clinically quiescent Crohn's disease. Gastroenterology2002;122(4 Suppl 1):A81. ">Mantzaris 2009</a>). However this result should be interpreted with caution as a GRADE analysis indicated that the overall quality of the evidence supporting this outcome was low due to sparse data (47 events) and high risk of bias (no blinding). There were no differences in withdrawals due to adverse events or serious adverse events. However, GRADE analyses indicated the quality of the evidence supporting these outcomes was very low due to very sparse data (two events for both comparisons) and high risk of bias. Further research is needed to allow any firm conclusions regarding the comparative efficacy and safety of azathioprine and budesonide for maintenance treatment in quiescent Crohn's disease. </p> <p>A pooled analysis of two studies (166 participants) found no difference between azathioprine (1.0 to 2.5 mg/kg/day) or 6‐mercaptopurine (1.0 mg/kg/day) and aminosalicylates (mezalazine 3 g/day or sulfasalazine 0.5 g/15 kg) in the proportion of patients who maintained remission at 12 months. A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was low due to sparse data (113 events) and high or unclear risk of bias. <a href="./references#CD000067-bbs2-0010" title="SingletonJ , LawD , KelleyM , MekhjianH , SturdevantR . National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology1979;77:870‐82. SummersRW , SingletonJW . National Cooperative Crohn's Disease Study (NCCDS): a controlled prospective trial of three drugs vs placebo. Gut1977;18(11):A972‐3. SummersRW , SwitzDM , SessionsJT , BecktelJM , BestWR , KernF , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77:847‐69. ">Summers 1979</a> was rated as unclear risk of bias for random sequence generation and incomplete outcome data and <a href="./references#CD000067-bbs2-0006" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero PernoaJ , Moreno OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12:1227‐33. ">Maté‐Jiménez 2000</a> was rated as high risk of bias for no blinding. A pooled analysis of two studies showed that antimetabolites (azathioprine or 6‐mercaptopurine) had a significantly increased risk of serious adverse events compared to aminosalicylates (mesalazine or sulphsalazine). However, a GRADE analysis indicated that the overall quality of the evidence supporting this outcome was very low due to sparse data (16 events) and high or unclear risk of bias. Further research with adequately powered trials is needed to allow any definitive conclusions regarding the comparative efficacy and safety of antimetabolites and aminosalicylates for maintenance therapy in Crohn's disease. </p> <p>One small study (31 participants) found no difference between 6‐mercaptopurine (1 mg/kg/day) and methotrexate (10 mg/week) in the proportion of patients who maintained remission at 72 weeks. A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was very low due to very sparse data (16 events) and high risk of bias. No differences were found with respect to adverse events, withdrawals due to adverse events, or serious adverse events. GRADE analyses indicated that the overall quality of the evidence supporting these outcomes was very low due to very sparse data (19, 5 and 5 events respectively) and high risk of bias. Moderate quality evidence from a single high quality trial indicates that intramuscular methotrexate at a dose of 15 mg/week is superior to placebo for maintenance of remission in Crohn's disease. The number needed to treat with methotrexate for an additional beneficial outcome was four (<a href="./references#CD000067-bbs2-0053" title="PatelV , WangY , MacDonaldJK , McDonaldJWD , ChandeN . Methotrexate for maintenance of remission in Crohn’s disease. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD006884.pub3] ">Patel 2014</a>). Only two small studies compare 6‐mercaptopurine to methotrexate for maintenance of remission in Crohn's disease (<a href="./references#CD000067-bbs2-0006" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero PernoaJ , Moreno OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12:1227‐33. ">Maté‐Jiménez 2000</a>; <a href="./references#CD000067-bbs2-0028" title="OrenR , MoshkowitzM , OdesS , BeckerS , KeterD , PomeranzI , et al. Methotrexate in chronic active Crohn's disease: a double‐blind, randomized, Israeli multicenter trial. American Journal of Gastroenterology1997;92(12):2203‐9. ">Oren 1997</a>), and no studies compare azathioprine to methotrexate. Further research with adequately powered trials is necessary to allow any conclusions regarding the comparative efficacy and safety of antimetabolites (azathioprine or 6‐mercaptopurine) and methotrexate for maintenance therapy in Crohn's disease. </p> <p>One small study (36 participants) found no difference in maintenance of remission rates at one year between combination therapy with azathioprine (2.5 mg/kg/day) and infliximab (5 mg/kg every 8 weeks) compared to infliximab monotherapy. A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was very low due to very sparse data (29 events) and high risk of bias. An adequately powered trial would be necessary to allow for any conclusions regarding the role of azathioprine as an adjunctive to infliximab maintenance therapy in Crohn's disease. There is moderate quality evidence that combination therapy with azathioprine and infliximab is superior to infliximab monotherapy for induction of remission in moderate to severe Crohn's disease (<a href="./references#CD000067-bbs2-0041" title="ChandeN , TsoulisDJ , MacDonaldJK . Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD000545.pub4] ">Chande 2013</a>; <a href="./references#CD000067-bbs2-0016" title="ColombelJ , SandbornW , ReinischW , MantzarisG , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ">Colombel 2010</a>). Furthermore, therapy with azathioprine and 6‐mercaptopurine may help to prevent the development of antibodies to infliximab. The development of antibodies to infliximab has been associated with infusion reactions and loss of response to infliximab. An analysis of the ACCENT I induction trial data by <a href="./references#CD000067-bbs2-0048" title="HanauerSB , WagnerCL , BalaM , MayerL , TraversS , DiamondRH , et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clinical Gastroenterology and Hepatology2004;2(7):542‐53. ">Hanauer 2004b</a> found that patients who received therapy with azathioprine, 6‐mercaptopurine or methotrexate in conjunction with infliximab had a significantly lower chance of developing antibodies to infliximab than patients who received infliximab monotherapy. Future maintenance trials assessing combination therapy should evaluate the interaction between antimetabolite (azathioprine or 6‐mercaptopurine) therapy and infliximab with respect to antibody formation and efficacy. </p> <p>One study (147 participants) failed to show any significant benefit for early azathioprine treatment over a conventional management strategy. In the early azathioprine treatment group 67% (11‐85%) of trimesters were spent in remission compared to 56% (29‐73%) in the conventional management group. The results of this trial need to be confirmed by another study. Further research is required to determine optimal management strategies for patients with quiescent Crohn's disease. </p> <p>The current review only included two studies where existing therapy was discontinued (<a href="./references#CD000067-bbs2-0003" title="ColombelJF , LemannM , BouhnikY , DuclosB , SouleJC , LereboursE , et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology2003;124(4 Suppl 1):A196‐7. LemannM , BouhnikY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. Randomized, double‐blind, placebo‐controlled, multicenter, azathioprine (AZA) withdrawal trial in Crohn’s disease (CD). Gastroenterology2002;122(4 Suppl 1):A23. LémannM , MaryJY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. A randomized, double‐blind, controlled withdrawal trial in Crohn's disease patients in long‐term remission on azathioprine. Gastroenterology2005;128(7):1812‐8. ">Lémann 2005</a>; <a href="./references#CD000067-bbs2-0007" title="O'DonoghueDP , DawsonAM , Powell‐TuckJ . Azathioprine as a maintenance treatment for Crohn's disease: a double blind withdrawal trial. Gastroenterology1978;72(5 II):1138. O'DonoghueDP , DawsonAM , Powell‐TuckJ , BownRL , Lennard‐JonesJE . Double‐blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet1978;2:955‐7. ">O'Donoghue 1978</a>). <a href="./references#CD000067-bbs2-0036" title="VilienM , DahlerupJF , MunckLK , NorregaardP , GronbaekK , FalligborgJ . Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following year. Alimentary Pharmacology and Therapeutics2004;19(11):1147‐52. ">Vilien 2004</a> which was excluded from this review, randomized patients to continue azathioprine therapy or to a no treatment control. The findings of this trial demonstrated that azathioprine was superior to no treatment for maintenance of remission (<a href="./references#CD000067-bbs2-0036" title="VilienM , DahlerupJF , MunckLK , NorregaardP , GronbaekK , FalligborgJ . Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following year. Alimentary Pharmacology and Therapeutics2004;19(11):1147‐52. ">Vilien 2004</a>). Future studies could randomize patients started on a maintenance regimen to discontinue therapy after a given amount of time spent in remission (i.e. randomize to groups based on when they stop taking azathioprine or 6‐mercaptopurine). These patients could then be analysed on time in remission on azathioprine or 6‐mercaptopurine and risk of relapse thereafter. Such trials would enable physicians to better explain to their patients their likelihood of relapsing if they stop therapy. Moreover, such trials would enable physicians to better weigh the risks of adverse events with therapy to the risk of relapse without therapy. </p> <p>We attempted to limit bias by performing a comprehensive literature search to identify all applicable studies. At least two review authors independently assessed studies for inclusion, extracted data and assessed study quality. However, the review does have some limitations. Only two of the included studies were rated as low risk of bias (<a href="./references#CD000067-bbs2-0003" title="ColombelJF , LemannM , BouhnikY , DuclosB , SouleJC , LereboursE , et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology2003;124(4 Suppl 1):A196‐7. LemannM , BouhnikY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. Randomized, double‐blind, placebo‐controlled, multicenter, azathioprine (AZA) withdrawal trial in Crohn’s disease (CD). Gastroenterology2002;122(4 Suppl 1):A23. LémannM , MaryJY , ColombelJF , DuclosB , SouleJC , LereboursE , et al. A randomized, double‐blind, controlled withdrawal trial in Crohn's disease patients in long‐term remission on azathioprine. Gastroenterology2005;128(7):1812‐8. ">Lémann 2005</a>; <a href="./references#CD000067-bbs2-0008" title="PanésJ , López‐SanrománA , BermejoF , García‐SánchezV , EsteveM , TorresY , et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology2013;145(4):766‐74. SansM , López‐San RomainA , EsteveM , BermejoF , Garcia‐SánchezV , TorresY , et al. Early use of azathioprine has a steroid sparing effect on recently diagnosed Crohn's disease patients. Gastroenterology2012;142(5 Suppl 1):S109. ">Panes 2013</a>). Three studies were rated as high risk of bias because they were not blinded (<a href="./references#CD000067-bbs2-0002" title="CosnesJ , BourrierA , BouhnikY , LaharieD , NahonS , BonnetJ , et al. Accelerated step‐care therapy with early azathioprine (AZA) vs. conventional step‐care therapy in Crohn's disease: a randomized study. Gastroenterology2012;142(5 Suppl 1):S161. CosnesJ , BourrierA , LaharieD , NahonS , BouhnikY , CarbonnelF , et al. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology2013;145(4):758‐65.e2; quiz e14‐5. ">Cosnes 2013</a>; <a href="./references#CD000067-bbs2-0005" title="MantzarisG , ChristidouA , SfakianakisM , RoussosA , KoilakouS , PetrakiK , et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn's disease. Inflammtory Bowel Diseases2009;15:375‐82. MantzarisGJ , PetrakiK , Chadio‐IordanidesH , ChristidouA , KaragiannidisA , GlarakisJ , et al. Maintenance therapy with azathioprine is superior to budesonide in healing endoscopic lesions and improving histology in clinically quiescent Crohn's disease. Gastroenterology2002;122(4 Suppl 1):A81. ">Mantzaris 2009</a>; <a href="./references#CD000067-bbs2-0006" title="HermidaC , CanteroJ , Moreno‐OteroR , Mate‐JimenezJ . Methotrexate and 6‐mercaptopurine in steroid‐dependent inflammatory bowel disease patients: A randomized controlled clinical trial. Gut1999;45(Suppl V):A132. Maté‐JiménezJ , HermidaC , Cantero PernoaJ , Moreno OteroR . 6‐mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology2000;12:1227‐33. ">Maté‐Jiménez 2000</a>). The remaining six studies were rated as unclear risk of bias for random sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting and other bias. Furthermore, GRADE analyses indicated that the overall quality of the evidence supporting the outcomes in this review ranged from low to very low quality. </p> </section> </section> <div class="figures-list"> <div class="figure" id="CD000067-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/urn:x-wiley:14651858:media:CD000067:CD000067-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_t/tCD000067-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD000067-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/full#CD000067-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000067-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/urn:x-wiley:14651858:media:CD000067:CD000067-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_t/tCD000067-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD000067-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/full#CD000067-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000067-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/urn:x-wiley:14651858:media:CD000067:CD000067-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_t/tCD000067-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Azathioprine versus placebo, Outcome 1 Maintenance of remission." data-id="CD000067-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Azathioprine versus placebo, Outcome 1 Maintenance of remission.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references#CD000067-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000067-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/urn:x-wiley:14651858:media:CD000067:CD000067-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_t/tCD000067-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Azathioprine versus placebo, Outcome 2 Maintenance of remission (sensitivity analysis excluding Candy 1995)." data-id="CD000067-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Azathioprine versus placebo, Outcome 2 Maintenance of remission (sensitivity analysis excluding Candy 1995). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references#CD000067-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000067-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/urn:x-wiley:14651858:media:CD000067:CD000067-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_t/tCD000067-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Azathioprine versus placebo, Outcome 3 Adverse events." data-id="CD000067-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Azathioprine versus placebo, Outcome 3 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references#CD000067-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000067-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/urn:x-wiley:14651858:media:CD000067:CD000067-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_t/tCD000067-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Azathioprine versus placebo, Outcome 4 Withdrawals due to adverse events." data-id="CD000067-fig-0006" src="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Azathioprine versus placebo, Outcome 4 Withdrawals due to adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references#CD000067-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000067-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/urn:x-wiley:14651858:media:CD000067:CD000067-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_t/tCD000067-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Azathioprine versus placebo, Outcome 5 Serious adverse events." data-id="CD000067-fig-0007" src="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Azathioprine versus placebo, Outcome 5 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references#CD000067-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000067-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/urn:x-wiley:14651858:media:CD000067:CD000067-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_t/tCD000067-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Azathioprine versus placebo, Outcome 6 Steroid sparing effect." data-id="CD000067-fig-0008" src="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Azathioprine versus placebo, Outcome 6 Steroid sparing effect.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references#CD000067-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000067-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/urn:x-wiley:14651858:media:CD000067:CD000067-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_t/tCD000067-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Azathioprine or 6‐mercaptopurine versus mesalazine or sulfasalazine, Outcome 1 Maintenance of remission." data-id="CD000067-fig-0009" src="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Azathioprine or 6‐mercaptopurine versus mesalazine or sulfasalazine, Outcome 1 Maintenance of remission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references#CD000067-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000067-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/urn:x-wiley:14651858:media:CD000067:CD000067-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_t/tCD000067-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Azathioprine or 6‐mercaptopurine versus mesalazine or sulfasalazine, Outcome 2 Adverse events." data-id="CD000067-fig-0010" src="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Azathioprine or 6‐mercaptopurine versus mesalazine or sulfasalazine, Outcome 2 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references#CD000067-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000067-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/urn:x-wiley:14651858:media:CD000067:CD000067-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_t/tCD000067-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Azathioprine or 6‐mercaptopurine versus mesalazine or sulfasalazine, Outcome 3 Withdrawals due to adverse events." data-id="CD000067-fig-0011" src="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Azathioprine or 6‐mercaptopurine versus mesalazine or sulfasalazine, Outcome 3 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references#CD000067-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000067-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/urn:x-wiley:14651858:media:CD000067:CD000067-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_t/tCD000067-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Azathioprine or 6‐mercaptopurine versus mesalazine or sulfasalazine, Outcome 4 Serious adverse events." data-id="CD000067-fig-0012" src="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Azathioprine or 6‐mercaptopurine versus mesalazine or sulfasalazine, Outcome 4 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references#CD000067-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000067-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/urn:x-wiley:14651858:media:CD000067:CD000067-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_t/tCD000067-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Azathioprine versus budesonide, Outcome 1 Maintenance of remission." data-id="CD000067-fig-0013" src="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Azathioprine versus budesonide, Outcome 1 Maintenance of remission.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references#CD000067-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000067-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/urn:x-wiley:14651858:media:CD000067:CD000067-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_t/tCD000067-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Azathioprine versus budesonide, Outcome 2 Withdrawals due to adverse events." data-id="CD000067-fig-0014" src="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Azathioprine versus budesonide, Outcome 2 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references#CD000067-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000067-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/urn:x-wiley:14651858:media:CD000067:CD000067-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_t/tCD000067-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Azathioprine versus budesonide, Outcome 3 Serious adverse events." data-id="CD000067-fig-0015" src="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Azathioprine versus budesonide, Outcome 3 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references#CD000067-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000067-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/urn:x-wiley:14651858:media:CD000067:CD000067-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_t/tCD000067-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Azathioprine + infliximab versus infliximab, Outcome 1 Maintenance of remission." data-id="CD000067-fig-0016" src="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Azathioprine + infliximab versus infliximab, Outcome 1 Maintenance of remission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references#CD000067-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000067-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/urn:x-wiley:14651858:media:CD000067:CD000067-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_t/tCD000067-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Azathioprine + infliximab versus infliximab, Outcome 2 Adverse events." data-id="CD000067-fig-0017" src="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Azathioprine + infliximab versus infliximab, Outcome 2 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references#CD000067-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000067-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/urn:x-wiley:14651858:media:CD000067:CD000067-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_t/tCD000067-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Azathioprine + infliximab versus infliximab, Outcome 3 Withdrawals due to adverse events." data-id="CD000067-fig-0018" src="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Azathioprine + infliximab versus infliximab, Outcome 3 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references#CD000067-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000067-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/urn:x-wiley:14651858:media:CD000067:CD000067-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_t/tCD000067-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Azathioprine + infliximab versus infliximab, Outcome 4 Serious adverse events." data-id="CD000067-fig-0019" src="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Azathioprine + infliximab versus infliximab, Outcome 4 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references#CD000067-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000067-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/urn:x-wiley:14651858:media:CD000067:CD000067-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_t/tCD000067-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 6‐Mercaptopurine versus methotrexate, Outcome 1 Maintenance of remission." data-id="CD000067-fig-0020" src="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 6‐Mercaptopurine versus methotrexate, Outcome 1 Maintenance of remission.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references#CD000067-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000067-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/urn:x-wiley:14651858:media:CD000067:CD000067-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_t/tCD000067-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 6‐Mercaptopurine versus methotrexate, Outcome 2 Adverse events." data-id="CD000067-fig-0021" src="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 6‐Mercaptopurine versus methotrexate, Outcome 2 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references#CD000067-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000067-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/urn:x-wiley:14651858:media:CD000067:CD000067-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_t/tCD000067-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 6‐Mercaptopurine versus methotrexate, Outcome 3 Withdrawals due to adverse events." data-id="CD000067-fig-0022" src="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 6‐Mercaptopurine versus methotrexate, Outcome 3 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references#CD000067-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000067-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/urn:x-wiley:14651858:media:CD000067:CD000067-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_t/tCD000067-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 6‐Mercaptopurine versus methotrexate, Outcome 4 Serious adverse events." data-id="CD000067-fig-0023" src="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 6‐Mercaptopurine versus methotrexate, Outcome 4 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references#CD000067-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/media/CDSR/CD000067/image_n/nCD000067-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD000067-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine versus placebo for maintenance of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Azathioprine or 6‐mercaptopurine versus placebo for maintenance of remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> maintenance of remission in Crohn's disease<br/> <b>Setting:</b> Outpatient<br/> <b>Intervention:</b> Azathioprine or 6‐mercaptopurine<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with azathioprine or 6‐mercaptopurine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maintenance of remission (sensitivity analysis excluding Candy 1995)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>617 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>734 per 1000<br/> (648 to 827) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.19<br/> (1.05 to 1.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>489<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>249 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>321 per 1000<br/> (254 to 408) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.29<br/> (1.02 to 1.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>359<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>78 per 1000<br/> (40 to 152) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.12<br/> (1.59 to 6.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>661<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>3,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>71 per 1000<br/> (35 to 142) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.45<br/> (1.22 to 4.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>556<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> VERY LOW<sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Placebo group risk estimate come from the placebo arm of meta‐analysis, based on included trials<br/> <sup>2</sup> Downgraded one level due to sparse data (327 events).<br/> <sup>3</sup> Downgraded one level due to unclear risk of bias. Five of the studies in the pooled analysis were rated as unclear risk of bias for random sequence generation, allocation concealment or incomplete outcome data.<br/> <sup>4</sup> Downgraded one level due to sparse data (104 events).<br/> <sup>5</sup> Downgraded two levels due to very sparse data (37 events).<br/> <sup>6</sup> Downgraded one level due to unclear risk of bias. Two of the studies in the pooled analysis were rated as unclear risk of bias for random sequence generation, allocation concealment, blinding or incomplete outcome data.<br/> <sup>7</sup> Downgraded two levels due to very sparse data (31 events). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine versus placebo for maintenance of remission in Crohn's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/full#CD000067-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000067-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine versus mesalazine or sulfasalazine for maintenance of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Azathioprine or 6‐mercaptopurine versus mesalazine or sulfasalazin</b> e<b>for maintenance of remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> maintenance of remission in Crohn's disease<br/> <b>Setting:</b> Outpatient<br/> <b>Intervention:</b> Azathioprine or 6‐mercaptopurine<br/> <b>Comparison:</b> Mesalazine or sulfasalazine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with mesalazine or sulfasalazine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with azathioprine or 6‐mercaptopurine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maintenance of remission</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>667 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>727 per 1000<br/> (587 to 894) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.09<br/> (0.88 to 1.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 8.77<br/> (0.54 to 142.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45<br/> (1 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>126 per 1000<br/> (59 to 270) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.86<br/> (0.87 to 3.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>290<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 9.37<br/> (1.84 to 47.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>235<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk estimate come from the control arm of meta‐analysis, based on included trials<br/> <sup>2</sup> Downgraded one level due to unclear and high risk of bias. One study was rated as unclear risk of bias for random sequence generation and incomplete outcome data and the other study was rated as high risk of bias for no blinding.<br/> <sup>3</sup> Downgraded one level due to sparse data (113 events).<br/> <sup>4</sup> Downgraded one level due to high risk of bias.<br/> <sup>5</sup> Downgraded two levels due to very sparse data (8 events).<br/> <sup>6</sup> Downgraded two levels due to very sparse data (28 events).<br/> <sup>7</sup> Downgraded two levels due to very sparse data (16 events). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine versus mesalazine or sulfasalazine for maintenance of remission in Crohn's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/full#CD000067-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000067-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Azathioprine versus budesonide for maintenance of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Azathioprine versus budesonide for maintenance of remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> maintenance of remission in Crohn's disease </p> <p><b>Setting:</b> Outpatient<br/> <b>Intervention:</b> Azathioprine<br/> <b>Comparison:</b> Budesonide </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with budesonide</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with azathioprine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maintenance of remission</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>462 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>762 per 1000<br/> (522 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.65<br/> (1.13 to 2.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.13<br/> (0.25 to 103.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.13<br/> (0.25 to 103.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk estimate come from the control arm of meta‐analysis, based on included trials<br/> <sup>2</sup> Downgraded one level due to high risk of bias (no blinding).<br/> <sup>3</sup> Downgraded one level due to sparse data (47 events).<br/> <sup>4</sup> Downgraded two levels due to very sparse data (2 events). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Azathioprine versus budesonide for maintenance of remission in Crohn's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/full#CD000067-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000067-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Azathioprine and infliximab versus infliximab for maintenance of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Azathioprine and infliximab versus infliximab for maintenance of remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> maintenance of remission in Crohn's disease<br/> <b>Setting:</b> Outpatient<br/> <b>Intervention:</b> Azathioprine<br/> <b>Comparison:</b> Infliximab </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with infliximab</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with azathioprine +</b> </p> <p><b>infliximab</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maintenance of remission</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>800 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>816 per 1000<br/> (592 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.02<br/> (0.74 to 1.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>160 per 1000<br/> (33 to 786) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.60<br/> (0.33 to 7.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.42<br/> (0.10 to 56.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.42<br/> (0.10 to 56.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk estimate come from the control arm of meta‐analysis, based on included trials.<br/> <sup>2</sup> Downgraded one level due to high risk of bias (single‐blind).<br/> <sup>3</sup> Downgraded two levels due to very sparse data (29 events).<br/> <sup>4</sup> Downgraded two levels due to very sparse data (6 events).<br/> <sup>5</sup> Downgraded two levels due to very sparse data (1 event). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Azathioprine and infliximab versus infliximab for maintenance of remission in Crohn's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/full#CD000067-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000067-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">6‐Mercaptopurine versus methotrexate for maintenance of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>6‐Mercaptopurine versus methotrexate for maintenance of remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> maintenance of remission in Crohn's disease<br/> <b>Setting:</b> Outpatient<br/> <b>Intervention:</b> 6‐mercaptopurine<br/> <b>Comparison:</b> Methotrexate </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with methotrexate</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with 6‐mercaptopurine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maintenance of remission</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>533 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>501 per 1000<br/> (251 to 987) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.94<br/> (0.47 to 1.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>407 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>265 per 1000<br/> (126 to 562) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.65<br/> (0.31 to 1.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>148 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>101 per 1000<br/> (25 to 407) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.68<br/> (0.17 to 2.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>148 per 1000<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>101 per 1000<br/> (25 to 407) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.68<br/> (0.17 to 2.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk estimate come from the control arm of meta‐analysis, based on included trials.<br/> <sup>2</sup> Downgraded one level due to high risk of bias (no blinding).<br/> <sup>3</sup> Downgraded two levels due to very sparse data (16 events).<br/> <sup>4</sup> Downgraded two levels due to very sparse data (19 events).<br/> <sup>5</sup> Downgraded two levels due to very sparse data (7 events). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">6‐Mercaptopurine versus methotrexate for maintenance of remission in Crohn's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/full#CD000067-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000067-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Azathioprine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Maintenance of remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.11, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Azathioprine dose 2.5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [1.08, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Azathioprine dose 2.0 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [1.10, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Azathioprine dose 1.0 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.84, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Maintenance of remission (sensitivity analysis excluding Candy 1995) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [1.05, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Azathioprine dose 2.5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.94, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Azathioprine dose 2.0 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [1.10, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Azathioprine dose 1.0 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.84, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [1.02, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>661</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [1.59, 6.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.45 [1.22, 4.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Steroid sparing effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.97, 2.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Azathioprine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references#CD000067-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000067-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine versus mesalazine or sulfasalazine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Maintenance of remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.88, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Azathioprine 2‐2.5mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.76, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Azathioprine 1.0 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.84, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 6‐mercaptopurine 1.5mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.13 [0.18, 24.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.77 [0.54, 142.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Azathioprine 2‐2.5mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Azathioprine 1.0 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 6‐Mercaptopurine 50mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.77 [0.54, 142.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [0.87, 3.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Azathioprine 2‐2.5mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.35, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Azathioprine 1.0mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.30 [0.95, 19.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 6‐mercaptopurine 50mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.65 [0.27, 81.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.37 [1.84, 47.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Azathioprine 2‐2.5mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.0 [1.15, 313.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Azathioprine 1mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.36 [0.26, 109.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 6‐mercaptopurine 50mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.65 [0.27, 81.01]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine versus mesalazine or sulfasalazine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references#CD000067-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000067-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Azathioprine versus budesonide</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Maintenance of remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Azathioprine versus budesonide</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references#CD000067-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000067-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Azathioprine + infliximab versus infliximab</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Maintenance of remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Azathioprine + infliximab versus infliximab</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references#CD000067-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000067-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">6‐Mercaptopurine versus methotrexate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Maintenance of remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">6‐Mercaptopurine versus methotrexate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000067.pub3/references#CD000067-tbl-0010">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD000067.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD000067-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD000067-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD000067-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD000067-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ru#CD000067-note-0002">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000067\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000067\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000067\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000067\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000067\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000067\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000067\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000067\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000067\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000067\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000067\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000067\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000067\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000067\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000067\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000067\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000067\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000067\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PMzGcYGP&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000067.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000067.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD000067.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD000067.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000067.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719212557"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000067.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719212560"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000067.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918de340681d9368',t:'MTc0MDcxOTIxNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 